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  Recent deorphanization of several G-protein-coupled receptors (GPRs) as 
endogenous receptors for free fatty acids (FFAs) has increased our understanding of 
these nutrients as signaling molecules and the integral role of gut microbiota in the 
regulation of host defense mechanisms, energy metabolism, gastrointestinal motility and 
secretion. There are five distinct FFA receptors (FFRAs: FFAR1, FFAR2, FFAR3, FFAR4 
and GPR84) that differ in molecular structure, ligand specificity, expression pattern, and 
functional properties. FFARs are grouped according to the chain length of FFAs that 
activate each FFAR. 
Enteric glial cells and enteroendocrine cells play a pivotal role in the secretion of 
gliotransmitters and peptide hormones, respectively, in response to specific stimuli. 
xvi 
 
Neurotrophins such as brain-derived neurotrophic factor (BDNF) are essential for the 
development and integrity of enteric nervous system in the gut and play an important role 
in the regulation of gastrointestinal functions including motility and secretion.  
The aim of this study was to identify the expression of FFARs in enteric glial cells 
and endocrine cells and determine the effects of fatty acids in the regulation of BDNF 
levels. Expression studies of FFARs by quantitative PCR, western blot and 
Immunohistochemistry from glial cells and enteroendocrine cells (STC-1 cells) 
demonstrated predominant expression of FFAR4 in STC-1 cells and predominant 
expression of FFAR1 in glial cells. Both FFAR1 and FFAR4 are activated by long-chain 
fatty acid. 
Activation of specific G protein(s) coupled to FFAR1 and FFAR4 and signaling 
pathways downstream of G proteins in response to the endogenous long chain fatty acid, 
linolenic acid (100 µM), demonstrated both FFAR1 and FFAR4 are coupled to Gαq and 
stimulation of PLC-β/IP3/ Ca2+ pathway. In enteroendocrine cells (STC-1) long chain fatty 
acids preferentially activate FFAR4, whereas in glial cells long chain fatty acids 
preferentially activate FFAR1. Furthermore, measurement of changes in BDNF levels in 
response to linolenic acid by immunocytochemistry and enzyme-linked immunosorbent 
assay (ELISA) demonstrated that in STC-1 cells, long chain fatty acids increased BDNF 
content via FFAR4, whereas in glial cells they increased BDNF content via FFAR1.  The 
present study shed light on the expression and physiological role of long chain fatty acids 




INTRORDUCTION AND BACKGROUND 
 
1. Introduction 
The gastrointestinal tract is a long muscular tube; approximately 6.5 meters (20 
feet) long, and is responsible for the digestion, absorption of nutrients, and expulsion of 
waste. The ingested food breaks down into small molecules and the movement of 
nutrients, water, and electrolytes from the lumen of the intestine into the blood require the 
major activities of gastrointestinal tract to be served. First of these is the gut motility, which 
is determined by the patterns of contraction and relaxation of the circular and longitudinal 
muscle layers to mix chyme with digestive enzymes and propel ingested food from the 
mouth toward the rectum. Second, the secretions of additional fluids, enzymes and mucus 
into the lumen from salivary glands, the cells of gastric mucosa, pancreas and liver are 
regulated. Motility and secretion further aid in digestion and absorption, which are the 
ultimate functions of the gastrointestinal tract. 
I.1 The Structure of The Gastrointestinal Tract Wall. 
 The digestive system is characterized by a wall contains four layers, from inside 
lining of the tract to the outside lining: the mucosa is the innermost layer, underneath is 
submucosa which is a loose connective tissue layer with blood vessels, nerves, lymphatic 
and secreting gland. The submucosa is then followed by the muscular propria which 
contains two layers of the smooth muscle; circular smooth muscle cells is the inner layer, 
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and the outer layer is longitudinal smooth muscle cells. The main function of smooth 
muscle of the gut is to mix and propel intraluminal contents allowing effective digestion of 
food, and absorption of nutrients. Finally the outermost layer – the serosa, is a serous 
membrane that covers the muscularis externa and comprises a loose connective tissue 
that is covered by the visceral peritoneum that contains blood vessels, lymphatic, and 
nerves.  
1.2 Enteric Nervous System 
 The human enteric nervous system (ENS) contains about 150 million nerve cells, 
comprising the largest division of the autonomic nervous system (Langley 1921). ENS 
provides confined neural control of the gastrointestinal tract and is essential in 
coordinating the digestive and defensive functions in the gut. A characteristic of ENS is 
that the nerve cell bodies located within the wall of the gut are organized into two 
ganglionated plexuses and nerve fibers throughout the external muscle layers, 
submucosa, and mucosa. The Myenteric plexus is located between the outer longitudinal 
and the inner circular smooth muscle layers of the muscularis externa and its neurons 
play a role in the gut motility. The submucosal plexus is located between the circular 
muscle layer and the muscularis mucosa and its neurons are involved in mucosal 
function, secretion, blood flow, and barrier function. Neurons of the ENS are supported 
by unique peripheral glial cells called enteric glia (Grundy and Brooks 1996). There are 
different classes of neurons in the ENS; motor neurons, classified as excitatory motor 
neurons that release acetylcholine or substance P as neurotransmitter or inhibitory motor 
neurons that release nitric oxide (NO) or vasoactive intestinal peptide (VIP) as transmitter. 
Both motor neurons innervate the muscle layer in the gut (Harmer, Fahrenkrug et al. 
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2012). In addition to motor neurons, there are sensory neurons, which have been 
classified as Dogiel type II neurons, which are characterized by multiple processes that 
via a complex of neuronal network that includs synaptic connections with interneurons, 
motor neurons and other sensory neurons (Grundy and Brooks 1996). 
1.3 Cells in the Gastrointestinal Tract. 
 There are multiple type of cells that line the gastrointestinal tract wall from the 
stomach to the anal sphincter. In the mucosal layer there are; enteroendocrine cells, 
brush cells, goblet cells, and paneth cells. Inflammatory cells are in the lamina propria, 
and in the muscularis externa there are smooth muscle cells, which also includes 
interstitial cells of Cajal, enteric neurons and glial cells. Each of them has different 
function. 
For example, the goblet cells are specialized cells scattered in the epithelium of the small 
intestine and colon. They are interposed between enterocytes and secret mucins which 
play role in mucosa curing and protection. Whereas, Paneth cells, are known for their 
location at the ends of the intestinal crypt. They play a role in the innate immunity system 
regulation of lamina microflora in the small intestine by secreting anti-microbial peptides 
into the crypt lumen, thereby providing protection for the stem cells that line the crypt 
walls. Other cells in mucosa such as brush cells are similar to other cells and they are 
specialized epithelial cells that are scattered within the epithelial lining of the 
gastrointestinal tract (Moore, B.A et al 2000; Kieta, A.V et al 2010). Moreover, smooth 
muscle cells in the gut are spindle shape cells, that contain actin and myosin, and are 
electrically coupled by gap junction for generating contractions. Also, interstitial cells of 
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Cajal (ICCs) are the gut pacemaker cells that creates electrical slow waves leading to 
smooth muscle contraction (Takaki M 2003).    
 However, two of the main cell types that have gained more attention recently are 
enteric glial cells and enteroendocrine cells.  
 
2. Enteric Glial Cells 
2.1 Historical Perspective on Enteric Glia Cells. More than 115 years ago, the 
first known description of the enteric glia was demonstrated by Dogiel in 1899. Yet, enteric 
glia were not clearly illustrated until just over 35 years ago when Giorgio Gabella for the 
first time addresed the structural relationship between enteric neurons and glia in enteric 
nervous system. He identified them as a unique class of cells and were name enteric glia 
cell (Gabella, 1981).  The word “glia” derives from the Greek word for “glue”. They were 
seen as a mere packing substance holding the enteric nervous system together (A Ruhl 
2005). 
The enteric glial cells are small cells with irregular stellate shape cell bodies and 
highly branched processes that extend from the cell body interposed throughout the 
neuropil. In addition, the composition of gliofilaments in enteric glia is predominantly 
composed of glial fibrillary acidic protein (GFAP) and vimentin (Jessen and Mirsky, 1983). 
There are four major types of enteric glia: 1) type I “protoplasmic” enteric gliocytes, 
the star-shaped enteric glia within enteric ganglia, 2) type II “fibrous” enteric gliocytes, the 
elongated glia within interganglionic fiber tracts, 3) type III “mucosal” enteric gliocytes 
associated with nerve fibers and epithelial cells at the level of the mucosa, and 4) type IV 
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“intramuscular” enteric gliocytes, the elongated glia associated with nerve fibers scattered 
between smooth muscle cells. (Liu et al, 2013).  
2.2 Function Roles of Enteric Glia. For a long time, enteric glial cells were 
believed to play role mainly as support cells for neurons. Over the past five years the 
importance of glial cells in the gut has been studied and this dogma has been gradually 
abandoned. Enteric glia cells are actively involved in modulating gut processes. They are 
a significant regulator of gut barrier maintenance which is required to protect the gut 
lumen from the invasion by bacteria, viruses or foreign substances. Dr. Brian Gulbransen 
in his enteric glia chapter remark that Type III enteric glial cells in the intestinal mucosa 
have an important role in maintaining the integrity of the mucosal barrier of the gut (A 
Ruhl 2005). Type I and Type II enteric gliocytes are important in the support of enteric 
neurons, they are involved in homeostatic control that maintain enteric 
neurotransmission. (Gulbransen and Sharkey, 2012). Additionally, enteric glia actively is 
involved in the regulation of neurotransmission and gliotransmission by participating in 
neurotransmitter synthesis or inactivation, which influence the gut function. Enteric glial 
cells may also contribute in the regulation of intestinal epithelial function; cell bodies and 
processes of enteric glial cells extend to the mucosal plexus and come in close contact 
with the epithelial cell layer.  
 There are some neurotrophins as well as neurotransmitters that are produced from 
enteric glial cells, such as, nerve growth factor (NGF), and glial cell-derived neurotrophic 
factor (GDNF) (Boyen et al, 2006; Korsak et al. 2012). The most well characterized 
neurotransmitter released from enteric glial cells is ATP, which has a potential role to 
trigger intracellular calcium waves and influence adjacent neurons, thus modulating 
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enteric neurotransmission (Zhang et al. 2007). Enteric glial cells also release nitric oxide 
(NO), the inhibitory neurotransmitter that has a physiological role in modulating epithelial 
ion transport (MacEachern et al. 2011 and Esposito et al, 2013). 
  The role of enteric neurons in the regulation of gastrointestinal function is well 
known, however the role of enteric glial cells in the regulation of gastrointestinal function 
has only recently started to be elucidated. Moreover, the current knowledge about enteric 
glial in the human gut health and disease is rather poor.  
 
3. Enteroendocrine Cells 
3.1 Characteristics of the Enteroendocrine cells.  The gastrointestinal tract is 
profoundly involved in the control of metabolism and motility via peptide hormones 
secreted from enteroendocrine cells scattered throughout the gut mucosa (Engelstoft MS, 
et al 2013). The endocrine system produces more than 20 different hormones from at 
least 10 distinct enteroendocrine cells that mediate effects through neuronal, auto, and 
paracrine mechanism.  
Enteroendocrine cells constitute the largest endocrine organ of the human body, 
they are a group of specialized epithelial cells distributed among mucosal cells of the 
gastrointestinal tract, that represent less than 1% of the mucosal cell population (Tongzhi 
Wu et al. 2013).  Enteroendocrine cells might be the first level of integration of information 
from the gut lumen, which act as specialized transducer of luminal factors, producing and 
secreting a variety of hormones or/and signaling molecules including: motilin, ghrelin, 
gastrin, somatostatin, cholecystokinin (CCK), glucose-dependent insulinotropic peptide 
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(GIP), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY). Each one of these 
hormones are released from different type of enteroendocrine cells which are differentially 
distributed in the gut. Such as I-cells and K-cells, that release cholecystokinin and 
glucose-dependent insulinotropic peptide, respectively, predominate in the proximal small 
intestine. Whereas, L- cells are present in highest concentration in the distal small 
intestine and colon which are responsible in glucagon-like peptide-1 (GLP-1) and peptide 
YY (PYY) release (Tongzhi Wu et al 2013).  
3.2 Classification of The Enteroendocrine Cells. There are two types of 
enteroendocrine cells that are observed in the gut. The first is an open cell type. In most 
of enteroendocrine cells exhibit the characteristic of open type structure, as they have 
microvilli extending to the gut luminal surface. Microvilli are directly in contact with gut 
lumen, providing the ability to sense luminal contents or increased the level of absorbed 
substances across the epithelial layer (Duca FA and Lam TK 2014). In addition to open 
cell type, there are closed cells that do not reach the lumen. Such as, ghrelin- secreting 
cells that do not come into contact with the gastric lumen (Parker HE et al. 2008). 
Moreover, enteroendocrine cells are known as chemoreceptors that sense ingested 
substances (nutrient and non-nutrients). Upon activation they induce changes in 
gastrointestinal function and food intake through the release of signaling substances 
acting on a variety of targets locally or at a distance.  
Hormones or peptides released from enteroendocrine cells possibly will 
communicate through paracrine fashion by interacting locally on specific receptors on 
vagal nerves or enteric neurons to activate afferent terminals or other cells. They can also 
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act in an endocrine fashion through the intestinal capillaries and the lymphatic system 
and on specific receptors located on more distant targets.  
3.3 Function Roles of Enteroendocrine Cells Secretion. The enteroendocrine 
cells are the first level of integration of information from the gut and are responsible for 
secreting an array of gut hormones that induce changes in gastrointestinal physiological 
function through the release of signaling molecules. The gut peptides released from 
enteroendocrine cells play a pivotal role in the regulation of multiple physiological 
responses including gastrointestinal motility and secretion, glucose level control, food 
intake, and gastric emptying. K cells secret glucose-dependent insulinotropic peptide, an 
incretin hormone, which stimulates glucose induced insulin release. I cells secrets 
cholecystokinin, which “was the first GI peptide for which a satiating effect was described” 
(Mansouri A 2014) by acting as a hunger suppressant. CCK mediates digestion in the 
small intestine by slowing gastric emptying. L cells secrets glucagon-like peptide-1, an 
incretin hormone. It plays an important role in promoting glucose homeostasis by 
augmenting insulin secretion, suppressing glucagon release and slowing gastric 
emptying, as well as by reducing food intake. In addition to glucagon like peptide-1, L 
cells secret peptide YY hormone that has physiological function in inhibiting the gastric 
motility (Parker HE et al. 2014). 
 
4.1 Neurotrophins 
 Originating from the greek words (trophe) meaning nourishment, neurotrophins are 
target-derived growth factors that regulate the survival, phenotypic differentiation, and 
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promote growth of axonal neurons in the central, peripheral, and enteric nerves system. 
There are four members of neurotrophic family; Nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 NT3 and neurotrophin-4 NT4 (Prakash et al 
2010). 
4.2 Brain-derived Neurotrophic Factor. Brain derived neurotrophic factor was 
the second discovered member of neurotrophins family of growth factor, which regulates 
the neuronal differentiation, migration, synaptic function. It also plays an important role in 
memory processes. Physiological functions of BDNF are initiated by binding to two 
classes of cell surface receptors; the first class is tropomyosin-related kinase (TrkB) 
receptor that binds to the BDNF with high affinity, the second class is the pan-
neurotrophin receptor (p75NTR) which binds to the BDNF with low affinity (Binder and 
Scharfman 2004) .  
4.3 Synthesis of BDNF. BDNF is synthesized as pre-pro-BDNF. On the rough 
endoplasmic reticulum (ER), the pre-BDNF single peptide is cleaved into pro-BDNF that 
is packaged in the Golgi, transported to the nerve terminal, stored in presynaptic vesicles 
and secreted from terminals in a stimulus-dependent manner. Neurotrophin-induced 
BDNF effects involve activation of TrkB that mediate PLCγ1 activation and IP3-induced 
mobilization of Ca+2 from the endoplasmic reticulum. Increase in intracellular Calcium 
causes secretion of BDNF (Hasbi A et al 2009).  
 Changes in BDNF components are associated with pathological conditions. The 
high BDNF level is related to lower stroke rate, Alzheimer’s, Parkinson’s disease, and 
depression (Hashimoto et al 2005). 
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4.4 BDNF in the Gut.  In the mature gastrointestinal tract of several species, such 
as human, rat, and mouse, the presence of BDNF and its receptors has been 
demonstrated. Expression of BDNF has been identified in enteroendocrine cells and 
enteric glial cells in the gut. Recent studies from Grider, et al 2006 have shown that 
stimulation of mucosa induces the release of BDNF which augments the release of 5-HT 
and calcitonin gene related peptide (CGRP), thus, enhancing the peristaltic reflex and 
gastrointestinal motility (Grider et al 2006). 
 Moreover, BDNF has an excitatory effect on colon, increase in the rate of colonic 
pellet propulsion has been observed. In human, BDNF increases gut motility, diarrhea, 
and bowel urgency. Changes in BDNF components in the gut are associated with 
inflammatory bowel disease, and it has been reported that increased BDNF levels were 
associated with ulcerative colitis (Massa SM et al 2010).  
 
5.1 Free Fatty Acids and Their Receptors  
 Free fatty acids are essential nutrients that have very important function as a 
source of energy, structural contribution to cellular components, and maintaining 
homeostasis under physiological and pathophysiological states. This is due to the 
contribution to coordinating expression of proteins involved in lipid uptake, synthesis, 
transport storage and degradation (Nilsson NE et al 2003). There are two types of fatty 
acids based on their formation: short chain free fatty acids that are primarily produced 
through the fermentation of indigestible fiber such as carbohydrates, oligosaccharides 
and resistant starch by anaerobic gut flora (Paul LE et al. 2003). The second type of fatty 
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acids have longer-chain fatty acids. They are the products of dietary intake, adipose 
recycling, and hepatic turnover of neutral fats and phospholipids (Wong JM et al. 2006). 
Also FFAs are categorized by the length of their carbon chain; short-chain fatty acids with 
carbon length less than 6 carbons, medium-chain fatty acid with carbon length between 
6-12 carbons, and long-chain fatty acids have more than 14 carbons. 
 The major component of short chain fatty acids in the human colon contains 
acetate (C2), propionate (C3), and butyrate (C4) with ratio of almost 3: 1: 1 respectively 
(Savage DC 1988). The total concentration of the short chain fatty acid is about 100 mM 
in the lumen of mammalian colon, yet the precise ratio is dependent on species and diet.  
In past decade, it has been reported that the sensor of free fatty acids are nuclear 
receptors, including peroxisome proliferator-activated receptor (PPARs) (Chawla A et al. 
2001). However, the free fatty acid effects on some biological processes have been 
suggested to involve cell surface receptors. Recent data have recognized free fatty acids as 
endogenous agonists for a small family of G-protein coupled receptors.  
5.2 Free Fatty Acids Receptors (FFARs) Five different membrane-bound free 
fatty acid receptors have been recently identified upon successful deorphanization 
strategy.  The free fatty acids receptor are G protein-coupled receptor (GPCRs) activated 
by free fatty acids. In the gastrointestinal tract these receptors for free fatty acids serve 
as nutrient sensor and differ in their ligand specificity, expression pattern, and functional 
properties (Kotarsky K et al. 2003). Short chain fatty acids (six or less carbon chain length) 
activate FFAR2, and FFAR3. GPR84 is activated by medium-chain free fatty acids, 
whereas both saturated and unsaturated medium- and long chain fatty acids activate 




FFAR1 is a G protein-coupled receptor recognized to be activated by medium to 
long chain saturated and unsaturated free fatty acids. The Briscoe group has reported 
that several free fatty acids work as agonists to FFAR1 in the micromolar concentration 
range. The potency of saturated free fatty acids to activate FFAR1 depends on their 
carbon chain length. However, the length of the carbon chain or the saturation degree 
doesn’t correlate with the potencies of the unsaturated fatty acids (Briscoe CP et al, 2003; 
Brown AJ et al. 2003; Itoh Y et al. 2003).   
5.3.1 Ligands. As mention previously, three separate groups reported that 
medium to long chain fatty acids activated FFAR1. The rank order of the agonists display 
most potency were as follows: docosahexaenoic acids (DHA, C22:6) > alpha-linolenic 
acid (C18:3) = oleic acid (C18:1) > palmitic acid (C16) and pentadeconic acid (C15). In 
addition to the natural ligands, several pharmacological studies reported novel series of 
FFAR1 agonists. GW9508 is a FFAR1 selective ligand used in many studies with 100-
fold more potent than at FFAR4 (Hara T et al 2013). The agonist activity of free fatty acids 
ligands has been evaluated by intracellular calcium response. Besides GW9508, Medica 
16, NCG75, PRARγ (thiazolidinedione) and TAK-857 have been reported as 
pharmacological ligands that activate FFAR1 (Hara T et al. 2011; Fukunaga S et al. 2006).  
5.3.2 Expression. FFAR1 expression was analysed by reverse-transcription 
polymerase chain reaction (RT-PCR), immunohistochemistry, and in situ hybridization 
techniques and revealed high level of FFAR1 expression in various tissues. Ubiquitous 
distribution of FFAR1 but with the highest expression was observed in the brain, then in 
the pancreas (Briscoe 2003). Moreover, FFAR1 mRNA has been detected in mammary 
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gland such as bovine mammary epithelial gland.  In particular FFAR1 shows high 
expression in the β cells (insulin producing pancreatic islet cells). Also, expression of the 
FFAR1 protein has been reported in the endocrine cells of gastrointestinal tract (Edfalk 
et al. 2008).  
5.3.3 Signal Transduction and Physiological Function. FFAR1 plays an 
important physiological role in the intestine by contributing to insulin secretion. It has been 
reported that activation of FFAR1 by medium to long chain fatty acids promotes glucose-
stimulated insulin secretion (GSIS) from pancreatic β cells. Various reports have 
confirmed that FFAR1 mediates the increase in intracellular calcium and the insulin 
secretion coupled to Gαq protein leading to activation of phospholipase C (PLC) and 
subsequent increase in the intracellular calcium concentration in β cells, which results in 
mobilization of calcium from endoplasmic reticulum (ER) leading to calcium influx through 
voltage-dependent L-type Ca2+ channel (VLTCC). 
Furthermore, activation of FFAR1 on endocrine cells of the gastrointestinal tract 
enhances insulin secretion indirectly through the release of incretin hormones, since 
receptors for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) are expressed in pancreatic β cells (Itoh et al. 2003; Edfalk 2008). 
Moreover, Efdalk et al 2008, have shown that oral fat diet administration to FFAR1-null 
mice results in an impaired secretion of both peptides; GLP-1 and GIP with a decrease in 
insulin secretion (Steneberg P et al. 2005; Shapiro H et al. 2005; Fujiwara K et al. 2005).  
Similarly, loss of the FFAR1 function via free fatty acids receptor 1 small interfering 
RNA (siRNA) treatment suppresses the insulin secretion in response to free fatty acid 
stimulation. Also, it has been reported that fatty acid stimulated-induced insulin secretion 
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was significantly decreased in FFAR1 knock out mice (Hara T et al. 2013). These reports 
suggest that FFAR1 plays a crucial role in the mechanism involved in the development of 
obesity and type 2 diabetes (Steneberg P et al. 2005; Shapiro H et al. 2005).  
5.4.1 FFAR2 
FFAR2 is a deorphanized G protein coupled receptor that has been identified to 
be activated with short chain free fatty acids for the first time in 2003.  Two separate 
groups (Brown et al. 2003 and Nilsson et al. 2003) have demonstrated during ligand 
fishing that FFAR2 was activated by the short chain fatty acid acetate. 
5.4.2 Ligands. Short chain fatty acid (SCFAs) with carbon length less than six 
carbons such as formate, acetate, propionate, butyrate, and pentanoate have been 
shown to be the endogenous agonists of FFAR2. However, this receptor shows 
differences in ligand specificity and tissue localization from FFAR3. The rank order of 
ligand potencies for FFAR2 activation was as follow: acetate = propionate > butyrate 
(Brown et al. 2003, Poul et al. 2003, and Nilsson et al. 2003). Recently it has been 
reported that different species show differences in the rank potency of short chain fatty 
acid ligands (Hansen et al 2012).   
5.4.3 Expression.  FFAR2 has been shown to be expressed in various tissues, 
in particular fat stores, inflammatory cells and the gastrointestinal tract (Hong 2005). 
Since short chain fatty acids are highly concentrated in the distal gastrointestinal tract it 
has been reported that FFAR2 is found in mucosal cells of the ileum and large intestine. 
Their pattern of expression is variable along the intestine and perhaps among various 
species (Tazo H et al. 2009 and Ulven T 2012). 
15 
 
5.4.4 Signal Transduction and Physiological Function.  Several reports have 
confirmed that stimulation of FFAR2 by short chain fatty acids lead to inhibition of cAMP 
production. Even though FFAR2 and FFAR3 have similar endogenous ligands, their G-
protein signaling mechanisms are different. Both the Gq pathway and the pertussis toxin 
sensitive Gi/o pathway are activated by FFAR2 (le Poul et al 2003). 
 As mention above, FFAR2 is highly expressed in adipose tissue. A series of 
studies has been made to understand the role of FFAR2 in adipocytes by Hang et al. 
There results suggested that activation of FFAR2 by short chain fatty acids inhibits 
lipolysis, and increases adipogenesis.   
Moreover, the Karaki group in 2008, by using reverse transcription polymerase 
chain reaction (RT-PCR) and immunohistochemistry detected colocalization of the 
FFAR2 with PYY (peptide YY) in mucosal epithelium and mast cells. These discoveries 
elucidate the crucial role of FFAR2 in the gastrointestinal tract. Prior studies have reported 
that short chain fatty acids stimulate the release of 5-HT and PYY from the ileum and 
colon (Karaki et al 2006). This led to the hypothesis that FFAR2 might contribute to these 
pathways as transduces between nutrient stimuli and satiety mediator release in distal 
gastrointestinal tract. Eventually FFAR2 might be a putative transducer of free fatty acid 
stimuli and have a therapeutic use in the treatment of numerous metabolic disorders, 







 FFAR3 is a deorphanized G protein coupled receptor reported for the first time in 
2003 by Brown et al. Similar to FFAR2, short chain fatty acids with carbon length less 
than six carbons have been demonstrated to be the endogenous agonist of FFAR3 
(Tazoe H et al. 2009). 
5.5.2 Ligands. FFAR3 was activated by short chain fatty acids. As mention in the 
previous section, the rank order of potencies with respect to activation of FFAR2 was as 
follow: acetate = propionate > butyrate. Whereas, that of FFAR3 was as follow: propionate 
> butyrate > acetate. Due to the low potency level of acetate in FFAR3 it has been used 
to distinguish between FFAR3 and FFAR2. Moreover, there are several pharmacological 
compound reported as FFAR3 agonist, such as, compound 5 (Leonard TW et al 2006). 
5.5.3 Expression. The initial expression studies using reverse transcriptase 
polymerase chain reaction detected highest levels of FFAR3 mRNA expression in the 
adipose tissue across a panel of human tissue (Xiong et al. 2004). In addition to its extra-
gastrointestinal localization, FFAR3 has been detected in the small and the large 
intestinal mucosa (Cohen P et al. 2001; Latour MG et al 2007). The FFAR3 expression 
also was found in the enteroendocrine cells of the distal small intestine (ileum) and the 
(proximal) colon (Karaki et al. 2006). 
5.54 Signal Transduction and Physiological Function. Various reports have 
confirmed that FFAR3 mediated the release of intracellular calcium and the 
phosphorylation of ERK1/2 (Le Poul et al 2003). Pertussis toxin treatment completely 
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abolished the intracellular calcium and ERK1 phosphorylation. Therefore, it has been 
suggested that the signaling mechanism activated by FFAR3 was coupled to Gi/o.  
 The analysis of FFAR3-deficient mice demonstrated that FFAR3 deficiency is 
associated with reduction of PYY (peptide YY) expression, increased intestinal transit 
rate, and reduction of extraction of energy obtained from short chain free fatty acids that 
are produced by the microbial fermentation of indigestible dietary polysaccharide (Samuel 
BS et al. 2008). These results suggest that FFAR3 regulates host energy balance through 
mechanisms that are dependent upon the microbiota (Xiong Y et al. 2004; Samuel BS et 
al. 2008; Karaki S et al. 2006). 
 Moreover, it has been reported that short chain fatty acids enhance leptin 
production by adipocytes. Leptin is a 16 kDa potent anorexigenic hormone produced 
mainly by fat cells, It acts via its receptors in the central nervous system to reduce food 
intake. Also, by using small interfering RNA treatment to knockdown the expression of 
FFAR3 mRNA, it has been found that FFAR3 knockdown almost totally abolished the 
ability of short chain fatty acids to induce leptin receptor expression and thus production 
of leptin. These results suggested that FFAR3 has a potential role in the regulation of 
feeding and obesity (Cherbut C et al. 1998; Cohen P et al. 2001). 
 
5.7.1 FFAR4 
 FFAR4 is a deorphanized G protein coupled receptor. By using a receptor 
internalization assay, medium to long chain free fatty acids were found to serve as 
endogenous ligands (Fukunaga et al 2006). The saturated free fatty acids with a carbon 
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length of 14 to 18 and unsaturated free fatty acids with a carbon length of 16 to 22 were 
detected to activate FFAR4 (Hirasawa et al 2005). 
5.7.2 Ligands. As mention above, FFAR4 is activated by medium to long chain 
free fatty acids ligands. Although most fatty acids that were shown to activate FFAR4 
were also able to activate FFAR1, the amino acids homology between both receptors was 
only 10% (Hara T et al. 2013).  Several pharmacological research reported a novel series 
of FFAR4 agonists. NCG21 was developed as the selective agonist for FFAR4. Other 
synthetic FFAR4 ligands have been reported recently, such as, TUG891, Compound 8 
and Compound 9 (Hara T et al. 2011; Fujiwara K et al. 2005). 
5.7.3 Expression.  Expression of FFAR4 has been abundantly found in the 
intestinal tract in both mice and human (Hirasawa et al 2005). FFAR4 is also expressed 
in the intestinal endocrine cell line STC-1 (Hirasawa et al. 2005; Tanaka et al. 2008; 
Miyauchi et al. 2009). Moreover, FFAR4 have been identified in adipocytes and 
macrophages (Oh DY et al. 2010). Activation of the receptor increases glucose uptake 
and adipogenesis in adipocytes cells whereas it exerted anti-inflammatory actions in 
macrophages (Gotoh et al. 2007). Moreover, FFAR4 expression has been reported in 
ghrelin cells and it may play a role in the lipid sensing cascade (Lu et al. 2012). 
5.7.4 Signal Transduction and Physiological Function.  Studies in HEK293 
cells have shown that both natural polyunsaturated fatty acids and synthetic ligands 
mediated the release of intracellular calcium. However, they did not change the cAMP 
production. FFAR4 is similar to FFAR1 is coupled to the Gq protein family. Moreover, it 
has been reported that FFAR4 activation induces PI3 kinase.  
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Hirasawa et al. used the STC-1 cell line to study the secretion of glucagon like 
peptide (GLP-1). They found that fatty acids such as alpha linolenic acid, 
docosahexaoienic acid, or palmitoleic acid activated FFAR4 to promote the release of 
GLP-1 from the STC-1 (Dockray GJ 2003). Since FFAR1 is also expressed in STC-1, 
they used small interfering RNA (siRNA) treatment to knockdown both receptors in order 
to identify which receptor was being activated by fatty acids. The results showed that the 
cells transfected with FFAR1 siRNA had no change in ability to release GLP-1 (Dockray 
GJ 2003). However, there was a significant decrease in GLP-1 release detected in cells 
transfected with FFAR4 siRNA. The ability of free fatty acids to cause release of GLP-1 
by the activation of FFAR4 introduced a new insight for alternative strategy in the 
treatment of diabetes (Hara T et al. 2011; Briscoe CP et al. 2006). 
 
5.6.1 GPR84 
 GPR84 is a recently discovered G protein coupled receptor that is specifically 
activated by medium chain free fatty acids, with carbon chain length of C9 to C14. (Wang 
J et al 2006). In contrast, neither short nor long chain free fatty acid activated GPR84.  
5.6.2 Ligands. GPR84 is activated by medium chain free fatty acids ligands. The 
most potent ligand with that activate for GPR84 are: capric acid (C10:0), undecanoic acid 
(C11:0), and lauric acid (C12:0) (Hirasawa A et al. 2008). 
5.6.3 Expression and Physiological Function.  Only few publications reported 
on the function of GPR84. It is selectively expressed in peripheral blood leukocytes. In 
addition, it has been reported that GPR84 is activated by medium chain free fatty acids 
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and is coupled to Gi/o pathway (Wang J et al 2006). Studies have shown that in 
monocytes/macrophages, medium chain fatty acids act via GPR84 to augment the 
stimulation of IL-12 production by lipopolysaccharide. Therefore, GPR84 might have 
important role in the free fatty acids metabolism to immune system regulation (Bouchard 


















 The importance of chemosensing in the gut to regulate several physiological 
functions is emerging with the advent of deorphanization of several G protein coupled 
receptors (GPCRs) for free fatty acids. There are five distinct free fatty acid receptors 
(FFAR1, FFAR2, FFAR3, GPR84, and FFAR4) that differ in ligand specificity, expression 
pattern, and functional properties. Recent studies have shown that these receptors serve 
as nutrient sensors and play an important role in a variety of physiological processes. In 
the gastrointestinal tract they contribute to the secretion of regulatory peptides from 
enteroendocrine cells. Therefore, free fatty acids are not only essential nutrients but also 
extracellular signaling molecules.  
Recent studies from our lab have shown that the release of brain-derived 
neurotrophic factor (BDNF) from enteroendocrine cells in response to luminal stimulation 
enhances the peristaltic reflex and gut motility. Release of BDNF from enteric glial cells 
is important for neuronal survival. However, the specific FFA receptors types and the 
signaling pathways involved in the release of paracrine agent is not known. In addition, 
the role of FFA receptors in the expression of BDNF content from enteroendocrine cells 
and enteric glial cells of the gastrointestinal tract is not known. In this context, we used 
biochemical, molecular, and functional approaches to investigating the expression of FFA 
receptors, their signaling pathway and their role in the regulation of BDNF content. The 
knowledge we gained from this study will generate a better understanding the mechanism 
by which FFA receptors works and the role of FFA receptors mediating BDNF. This can 
also aid in the development of agonist which can help in the therapy of Gut motility 




HYPOTHESIS AND SPECIFIC AIMS 
 
  
 The following are the Specific Aims and underlying hypotheses.  
 Specific Aim 1:  To determine the expression of the free fatty acids receptors 
(FFARs) in enteroendocrine cells (STC-1), glial cells, and in mouse intestinal cells.  
 Hypothesis.  Receptors for free fatty acids are differentially expressed in 
enteroendocrine cells and glial cells and in different regions of the gastrointestinal tract.  
 
 Specific Aim 2: To determine the downstream signaling pathway involved in 
long chain FFAR1 and FFAR4 in enteroendocrine cells (STC-1) and enteric glial cells.  
 Hypothesis.  Signaling pathway of activated FFAR1 and FFAR4 in both STC-1 
and enteric glial cells is mediated via stimulation of PLC/IP3/Ca+2 pathway. 
 
 Specific Aim 3:  To determine the role of long chain FFA receptors in the 
regulation of brain derived neurotrophic factor content in STC-1 and enteric glial cells. 
 Hypothesis.  Activation of FFAR1 and FFAR4 induces increase in BDNF content 





MATERIAL AND METHODS 
 
2.1.1 Materials 
 Linolenic acid (LA) and GW9508 were obtained from Sigma-Aldrich (St Louis, Mo), 
TUG891 was obtained from TOCRIS Bioscience (Bristol, UK) and GW1100 was obtained 
from Cayman Chemical Company (Ann Arbor, MI). [35S] GTPγS, myo-[3H] inositol were 
obtained from Perkin Elmer (Boston, MA); antibodies to FFAR1, FFAR2, FFAR3, , 
FFAR4, GPR84, , BDNF, GAPDH, β actin, GFAP, S100, Gαq, and Gαi1-3, were obtained 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); the BDNF Emax® ImmunoAssay 
System was obtained from Promega Corporation (Promega Corporation, WI); U73122 
(PLC inhibitor) was obtained from Calbiochem ( La Jolla, CA); Fura 2-AM, was obtained 
from Invitrogen (Eugene, OR);  western blotting, Dowex AG-1 X 8 resin (100-200 mesh 
in format form), chromatography material and protein assay kit were obtained from Bio-
Rad Laboratories (Hercules, CA); RNAqueousTM kit was obtained from Ambion (Austin, 
TX); PCR reagents were obtained from Applied Biosystems (Foster city, CA); SuperScript 
MT II Reverse Transcriptase was obtained from Invitrogen (Carlsbad, CA); Dulbecco’s 25 
modified Eagle’s medium (DMEM) was obtained from Fisher Scientific. Fluorescence-
conjugated species-specific secondary antibody Alexa 488 and Alexa 594 were obtained 
from Li-Cor (Lincoln, NE). siRNA FFAR1, siRNA FFAR4 and siRNA control were obtained 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). STC-1 cell line were obtained from 
mouse musculus and enteric glial cells line were obtained from rat jejunum from ATCC.  




2.1.2 Tissue Collection 
Wild type adult C57BL/6J mice were purchased from Jackson Laboratories (Bar 
Harbor, ME).  Animals were killed by CO2 inhalation/asphyxiation by placing them in 
sealed chamber with a CO2 flow into the chamber at ~20% volume displacement per 
minutes for ~ 5 minutes, Tissues (small intestine and colon) were immediately dissected 
and used for immunohistochemistry. The animal was housed in the animal facility 
administrated by the Division of Animal Resources, Virginia Commonwealth University. 
All procedures were conducted in accordance with the Institutional Animal Care and Use 
Committee of the Virginia Commonwealth University. 
 
2.1.3 Expression of free fatty acid receptors (FFAR) in STC-1 and glial cells by RT-
PCR 
Total RNA was isolated from both STC-1 and enteric glial cells with Ambion RNA 
isolation kit. RNA from each preparation was reversely transcribed using the 
SuperScript™ II system containing 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 
10 mM dithiothreitol (DTT), 0.5 mM deoxynucleoside triphosphates (dNTP), 2.5 μM 
random hexamers and 200 units of reverse transcriptase in a 20 μl reaction volume. The 
reactions were carried out at room temperature for 10 min at 37°C for 120 min, and 
terminated by heating at 85°C for 5 min. Three μl of the reversely transcribed cDNA was 
amplified in a final volume of 50 μl by PCR in standard conditions (2 mM MgCl2, 200 μM 
dNTP, 2.5 units Q5 High-Fidelity DNA Polymerase) with specific primers designed based 
on rat and mouse cDNAs. PCR was performed for 35 cycles. For each experiment, a 
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parallel control without reverse transcriptase was processed. The amplified PCR products 
were analyzed on 1.5% agarose gel containing 0.1 μg/ml ethidium bromide. 
 
2.1.4 Expression of FFAR1 and FFAR4 in STC-1 and glial cell by quantitative PCR 
(qRT-PCR) 
Quantitative PCR was performed using StepOne™ Real-Time PCR System 
(Applied Biosystem, Foster city, CA) and the intercalating dye, SYBRgreen. For each 
cDNA sample, real-time PCR was conducted in a 20 μl reaction volume containing 
QuantitectTM SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). The following time 
and temperature profiles were used for the real-time PCR reactions: 95 ˚C for 5 min; 50 
cycles of a series consisting of 15 s at 94 ˚C, 30 s at 52 ˚C, 30 s at 72 ˚C; and a final 
extension of 5 min at 72 ˚C. The optimal annealing temperatures were determined 
empirically for each target and endogenous control (housekeeping gene) primer set. 
Real-time PCR reactions were performed in triplicate. The fluorescent threshold value 
was calculated using the StepOne™ Real-Time PCR System software. The absence of 
peaks in water controls suggested a lack of primer-dimer formation. 
Two general types of quantification strategies were performed in quantitative RT-
PCR (qRT-PCR). The levels of expressed genes were measured by an absolute 
quantification or by a relative qRT-PCR. The absolute quantification approach relates the 
PCR signal to input copy number using a calibration curve. Relative quantification relates 
the PCR signal of the target transcript in a treatment group to that of another sample such 
as an untreated control. Relative quantification of a target gene in relation to another gene 
(reference gene or housekeeping gene) was calculated on the basis of delta delta CT 
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values (CT, called as well CP), is the cycle number at which the fluorescence generated 
within a reaction crosses the threshold. CT reflects the point during the reaction at which 
a sufficient number of amplicons has accumulated). The target-gene expression is  
Delta delta CT method ΔΔCT = (CT, Tag − CT, HKG) Treatment − (CT, Tag− CT, HKG) Control 
Relative gene expression (Fold Change) = 2−ΔΔCT 
Where, HKG is the housekeeping gene and Tag, the evaluated gene. 
After normalization, the data for free fatty acid receptors were expressed as the fold-
change in mRNA expression relative to that obtained from control samples. 
 
2.1.5 Protein extraction 
 STC-1 and enteric glial cells were homogenized with solubilizing buffer of the 
following composition, T-PER (tissue protein extraction reagent) plus protease and 
phosphatase cocktail inhibitors. The supernatant was collected after sonication for 15 
seconds and centrifugation at 10000g for 10 minutes at 4 °C. Then the protein 
concentration was determined by DC protein assay kit from Bio-Rad (a colorimetric assay 
to detect protein concentration after detergent solubilization based on Lowery assay). 
 
2.1.6 Expression of free fatty acid receptors by Western blot 
 Equivalent amount of proteins were fractionated by SDS/PAGE electrophoresis 
using 10% (w/v) acrylamide resolving gel and the separated proteins were 
electrophoretically transferred onto a nitrocellulose membrane. The membrane was 
blocked by incubation in 5% non-fat dried milk + Tris buffered saline with 0.1% tween-20 
(TBST) for one hour at the room temperature. The membrane was incubated overnight 
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at 4 ̊ C with various primary antibodies diluted in TBS-T 5% (w/v) non-fat dried milk (Table 
2). The blots were washed three times for five minutes with TBS-T and then the 
membrane was incubated with horseradish-peroxidase-conjugated to IRDye 800CW  or 
680 (LI-COR) corresponding secondary antibodies diluted to 1:20000 in 5% non-fat dry 
milk + TBS-T for two hours with gentle shaking at room temperature. The membrane was 
washed three times for five minutes with TBS-T, then the immunoreactive proteins were 
visualized by using Super Signal Femto maximum sensitivity substrate kit (Pierce, IL). 
 Quantification of protein bands obtained on western blot was done using the 
ODYSSEY infrared imaging system (LI-COR Biosciences). To maintain equal amount of 
loaded proteins, the average intensity obtained of each band was normalized to its 
respective band of β-actin. The average bands intensity were then presented as relative 
fold changes compared with the control of the same lane.  
 
2.1.7 Colocalization of free fatty acid receptors with BDNF in STC-1 and glial cells 
by Immunocytochemistry 
STC-1 or glial cells were cultured in 8-well chamber slide for two days and treated 
with free fatty acid receptor agonists for 15 minutes. Cells were fixed in 4% 
paraformaldehyde for 30 minutes at room temperature. After permeabilization with 0.3% 
Triton X-100 for 5 minutes and blocking with 5% normal  donkey serum (Jackson 
ImmunoResearch, PA) in PBS for 30 minutes (pH 7.4), cells were incubated with FFAR1 
or FFAR4 antibodies along with BDNF antibodies for two hours at room temperature. 
Cells were rinsed twice in PBS and then incubated with fluorochrome-conjugated 
secondary antibodies Alexa 594 or 488 for one hour at room temperature. Cells were 
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rinsed four times with PBS, then mounted with mounting buffer with DAPI on glass 
microscope slides and analyzed under a Zeiss fluorescent photomicroscope. 
Immunostaining in the absence of primary or secondary antibody was assessed for 
background evaluation.  
 
2.1.8 Histology and tissue Immunofluorescence  
 About 4 cm long pieces of mouse intestinal and colon samples were cleaned with 
smooth muscle buffer of the following composition (NaCl 120 mM, KCl 4 mM, KH2PO4 
2.6 mM, CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2-hydroxyethylpiperazine-N’ 2-
ethanesulfonic acid) 25 mM, glucose 14 mM, and essential amino mixture 2.1% (pH 7.4). 
and placed in 4% paraformaldehyde fixative solution overnight at 4 ˚C. After fixation the 
tissue was placed on to pre-labeled tissue base mold, the entire tissue block was covered 
with cryo-embedding media (OCT), and then stored in -80 ˚C. Then, cross sections (10 
µm) were cut and mounted on gelatin-coated microscope slide. The slides were warmed 
at 37 ˚C for one hour and then fixed with cold acetone for 10 minutes. The tissue were 
blocked with blocking solution containing 3% of normal donkey serum in PBS. The slides 
then were incubated with primary antibodies (1:200 dilution) diluted in PBS containing 5% 
normal donkey serum at 4 ˚C overnight. After rinsing three times with 0.1% IHC-PBS, the 
sections were incubated with fluorescence-conjugated species-specific secondary 
antibody Alexa 488 for two hours at room temperature.  Tissue sections were rinsed three 
times in IHC-PBS with and without 0.1% tween-20. Then slides were mounted with 
Citiflour antifadent mounting medium. Control sections were incubated without the 
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primary antibody to evaluate nonspecific binding. Prepared slides were viewed with an 
AxioCam Carl Zeiss microscope.   
 
2.1.9. Assay for G protein activation 
  G proteins selectively coupled to FFAR1 and FFAR4 were identified from the increase 
in G binding to the [35S] GTPS (5’-O-3-thiotriphosphate) using the method of Okamoto et al 
2000.  Ten ml of STC-1 or glial cells suspension (3 X 106 cells/ml) were homogenized in 20 
mM HEPES medium (pH 7.4) containing 2 mM MgCl2, 1 mM EDTA and 2 mM DTT.  After 
centrifugation at 30,000 g for 15 min, the crude membranes were solubilized for 60 min at 4 
C in 20 mM HEPES medium (pH 7.4) containing 2 mM EDTA, 240 NaCl, 0.5% CHAPS (3-
[(3-cholamidopropyl) dimethylammonio]-1-pro-panesulfonate), 2 mM PMSF, 20 μg/ml 
aprotinin, and 20 μM leupetin.  The membranes were incubated for 20 min at 37 C with 60 
nM [35S] GTPS with 100 μM linolenic acid in the presence or absence of FFAR1 (GW1100, 
10 μM) or FFAR4 (AH7614, 100 μM) antagonists in a solution containing 10 mM HEPES (pH 
7.4), 100 M EDTA and 10 mM MgCl2.  The reaction was terminated with 10 volumes of 100 
mM of Tris-HCl medium (pH 8.0) containing 10 mM MgCl2, 10 mM NaCl and 10 M GTP, and 
the mixture was placed in wells precoated with specific antibodies to Gq or Gi1-3. Coating 
with G protein antibodies (1:1000) was done after the wells were first coated with anti-rabbit 
IgG (1:1000) for two hours on ice. After incubation for two hours on ice, the wells were washed 
three times with phosphate buffer saline solution (PBS) containing 0.05% Tween-20  followed 
by solubilization with 0.1N NaOH and the radioactivity from each well was counted by liquid 
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scintillation.  The amount of [35S] GTPγS bound to the activated G subunit was expressed 
as counts per minute (cpm). 
 
2.1.10. Assay for phosphoinositide (PI) hydrolysis (PLC-β activity)  
PI hydrolysis (PLC-β activity) was determined in STC-1 and glial cells by measuring 
the formation of inositol phosphates using ion-exchange chromatography using the 
method of Berridge et al as described previously (Murthy and Makhlouf 1991; Murthy, 
Zhou et al. 2003). STC-1 and glial cells were labeled with [3H] myo-inositols (0.5 μCi/ml) 
for 24 hours in inositol-free DMEM medium. The cultures were washed three times with 
phosphate-buffer saline (PBS) and treated with long-chain free fatty acids receptor 
agonists or antagonists; linolenic acid, GW9508, TUG891, GW1100, AH7614 or U73122 
( PI hydrolysis inhibitor) for one minute. The reaction was terminated by the addition of 
940 μl chloroform-methanol-HCl (50:100:1 v/v/v). After chloroform (310 μl) and water (310 
μl) were added, the samples were vortexed and the phases were separated by 
centrifugation at 3000 rpm for 20 minutes. The upper aqueous phase was applied to the 
column containing 1 ml of 1:1 slurry of Dowex AG-1 X8 resin (100-200 mesh in formate 
form) and distilled water.  
The column was washed with 10 ml of water followed by 10 ml of 5 ml sodium 
tetraborate-60 mM ammonium formate to remove [3H] glycerophosphoinositol. Total 
inositol phosphates were eluted with 6 ml of 0.8 M ammonium formate-0.1 M formic acid. 
The eluates were collected into scintillation vials and counted in gel phase after addition 




2.1.11 Measurement of [Ca2+]i  
 Free fatty acid receptor agonists-induced increase in [Ca2+]i was measured by 
fluorescence in single STC-1 or glial  cells loaded with fluorescent Ca2+ dye fura 2-AM. 
STC-1 or glial cells were plated on coverslips for 12 h in DMEM. After being washed with 
PBS, the cells were loaded with 5 µM fura 2-AM in HEPES containing 10% pluronic and 
DMSO for 3 hours at room temperature. Clusters of cells were selected for imaging and 
visualized. The cells were visualized through a 40 objective (ZEISS; 0.9 NA) with a Zeiss 
Axioskop 2 plus upright fluorescence microscope and imaged with a setup consisting of 
a charge coupled device camera (Imago, TILL Photonics, Applied Scientific 
Instrumentation, Eugene, OR) attached to an image intensifier. The cells were 
alternatively excited at 340 nm and 380 nm and the emitted light was detected using a 
dichroic mirror (410 nm) and emission filter (530). The increase in Ca2+ is related to an 
increase in FIR (FIR= Fluorescence Intensity Ratio). The increase in intracellular calcium 
in response to LA and FFAR1 (GW9508) and FFAR4 (TUG891) agonists was measured 
by determining the ratio of the fluorescence of fura-2 AM at 340 and 380 nm excitation 
(F340/F380).  
 
2.1.12. Transfection of FFAR1 siRNA or FFAR4 siRNA 
 STC-1 or glial cells were plated in six-well plates and cultured until confluent. Antibiotic 
free medium was used one day before the transfection. The cells were then transiently 
transfected with the FFAR1 siRNA or FFAR4 siRNA by using Lipofectamine 2000 for 24 hours 
according to the manufacturer’s instructions (Invitrogen). Briefly, 100 pmol of the siRNA in 
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125 µl OptiMEM medium were mixed with 5 µl of Lipofectamine 2000 in 125 µl of Opti-MEM. 
The mixture was incubated at room temperature for 20 min and added to wells containing 1.5 
ml DMEM with 10% FBS for one day. The medium was then replaced with DMEM with 10% 
FBS plus antibiotics for two days. Cells were maintained for a final 24 hours in DMEM without 
FBS before experiments were started. Transfection efficiency was monitored by the 
expression of the red fluorescence protein using FITC filters. Control cells were transfected 
with vector alone. Analysis by psiREN DS-RED with fluorescence microscopy showed that 
approximately 80-90%.of the cells were transfected. 
 
2.1.13. Measurement of BDNF content by enzyme-linked immunosorbent assay 
(ELISA) 
STC-1 or glial cells were plated in 6 wells plate with DMEM containing 5% FBS 
and antibiotics and cultured until 80-90% confluent. The cells were washed with DMEM 
0 for 30 minutes. Cells were then treated for 15 minutes in DMEM 0 containing 1% 
albumin, amastatin, and phosphoramidon with or without 100 µM linolenic acid, 10 µM 
GW9508, 10 µM GW1100, 100 µM TUG891, or 100 µM AH7614. Cells were washed with 
PBS and solubilized in Triton X-100 based lysis buffer plus protease and phosphatase 
inhibitors. After centrifugation of the lysates at 14000 rpm for 10 minutes at 4 °C, the 
protein concentration from the pellet were determined with a Dc protein assay kit from 
Bio-Rad. 
BDNF content in the STC-1 cells and glial cells was measured via a sandwich 
ELISA using the Promega (Promega Corporation, WI) BDNF Emax immunoassay 
according to the manufacturer’s directions. Polystyrene ELISA plates were coated with 
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anti-BDNF mAb (1:1000) by adding 100 µl of the antibody to each well and overnight 
incubation at 4 °C without shaking. The plate was vigorously washed on the next day with 
TBST and blocked by adding 200 µl of block & sample 1X buffer to each well using a 
multichannel pipettor and incubated for one hour at room temperature without shaking. 
One hundred microliters of treated samples and BDNF standards were added in duplicate 
and incubated with shaking for two hours at room temperature. The plate was washed for 
five times and then incubated with 100 µl of anti-human BDNF pAb (1:500) at room 
temperature for two hours with shaking. After five times washing of the plate with TBST, 
100 µl of diluted anti-IgY HRP Conjugate (1:200) were added to each well and the plate 
incubated for another two hours with shaking at room temperature. Then the plate was 
washed five times and 100 µl of room-temperature TMB One solution (3,3′,5,5′-
tetramethylbenzidine), the substrate was added and incubated for 10 minutes with 
shaking. One hundred microliters of 1N hydrochloric acid were added to wells to stop the 
reaction. Then the plate was scanned using a plate reader and the absorbance was 
measured at 450 nm within 30 minutes of stopping the reaction. The BDNF levels were 




 The results were expressed as means  SE and the experiments were performed 
at least five times.  Statistical significance was analyzed using Student’s t-test for paired 
and unpaired values. The results were statistically analyzed using GraphPad Prism 
software, San Diego, CA. A probability of P < 0.05 was considered significance.  
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Table 1. Sequence of primers used for PCR, GAPDH; Glyceraldehyde 3-phosphate 
dehydrogenase, -actin, FFAR: free fatty acid receptor, m:mouse, r:rat. 
 
Primer set Forward Primer 5’  3’ Reverse Primer 3’  5’ 
Size 
(bp) 
m/FFAR1 AATGCCTCCAATGTGGATAG AGTCCTCGTCACACATATTG 159 
m/FFAR3 TCCTGGCATCGGCTCACT TGTAGGTTGCATTTCCCCAGTA 62 
m/FFAR2 ACCAAATCACCTGCTATGAGAACTT CACGGGCAGCACCACAT 58 
m/GPR48 CCCCCTCTGGAATGTTTTTGT TCGCATGCGTCAAAGC 63 
m/FFAR4 GCATAGGAGAAATCTCATGG GAGTTGGCAAACGTGAAGGC 335 
r/β-actin CAGGGTGTGATGGTGGGTATG AGTTGGTGACAATGCCGTGTT  
r/GAPDH AAGGTGGTGAAGGAGGCGGC GAGCAATGCCAGCCCCAGGA  
r/FFAR1 ACTGGTCACTGGCTACTTGG TTGGAGTCCTGGTCACACAT 65 
r/FFAR3 GCAGTCTTTCCGTCATGCCT TCCCTGAAGGTCTCTCCCAG 140 
r/GPR84 AAGTGCATCGCAAGACTGGA CTGAGGACGAAGCAAAGGAAC 156 
r/FFAR4 AATCGCACCCACTTCCCTTT GATGAGTCCCAGAACGGTGG 90 









Table 2. Source and concentration of primary antibodies used and the product size 
of the proteins identified  
 
 







sc-32905 31 Santa Cruz 1:1000 
FFAR3 sc-98332 39 Santa Cruz 1:1000 
FFAR2 sc-32906 43 Santa Cruz 1:1000 
GPR84 sc-99106 44 Santa Cruz 1:1000 
FFAR4 sc-99105 52/42 Santa Cruz 1:1000 
β-actin  42 Sigma 1:1000 













3.1 Expression of Free Fatty Acid Receptors (FFARs) 
Receptors for short-, medium- and long-chain free fatty acids (FFAs) belong to 
relatively newly deorphanized G protein coupled receptor family and recent evidence 
suggests that these receptors play a role in the regulation of gastrointestinal function such 
as motility and secretion, and energy metabolism.  FFARS are grouped according to the 
chain length of FFAs that activate each FFARs.  FFAR1 and FFAR4 are preferentially 
activated by medium- and long-chain FFAs, but preferentially activated by long-chain 
FFAs.  FFA2 and FFA3 are activated by short-chain FFAs, whereas GPR84 is activated 
by medium-chain, but not long-chain FFAs.   
In the present study, we analyzed the mRNA and protein expression of FFAR1, 
FFAR2, FFAR3, FFAR4 and GPR84 in mouse endocrine cells (STC-1 cells) and rat 
enteric glial cells by RT-PCR, real time RT-PCR, and Western blot, and by 
immunohistochemistry in mouse small intestine.  
 
3.1A. Expression of FFAR1, FFAR2, FFAR3, FFAR4 and GPR84 mRNA in STC-1 and 
Enteric Glial Cells 
(i) RT-PCR. Primers for RT-PCR analysis of FFARs in STC-1 cells and glial cells 
are based on rat FFARs sequences, The sequence of specific primers are listed in 
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chapter 2 table 1.Messenger RNA for FFAR1 (159 bp), FFAR2 (58 bp), FFAR3 (62bP), 
FFAR4 (335 bp) and GPR84 (63 bp) were detected by RT-PCR analysis of RNA isolated 
from STC-1 cells (Figure 3). Under similar condition, mRNA for FFAR1 (65 bp), FFAR3 
(114 bp), FFAR4 (90 bp) and GPR84 (156 bp) were detected by RT-PCR analysis of RNA 
isolated from glial cells (Figure 4). The results suggest expression of all FFARs in both 
enteroendocrine cells and enteric glial cells.  
(ii) Real-time RT-PCR. For comparative analysis of FFARs in STC-1 and glial 
cells, quantitative real time PCR was performed in triplicate in RNA isolated from both 
STC-1 and enteric glial cells. Expression of FFAR4 was 5.3 fold higher compared to other 
FFA receptors in STC-1 cells (Figure 5). In contrast, expression of FFAR1 was 2 fold 
higher compared to FFAR4 in glial cells. (Figure 5). These results suggest differential 
expression of FFAR1 and FFAR4 in in enteroendocrine and enteric glial cells. 
3.1B. Expression of FFAR1 and FFAR4 protein in STC-1 and Glial Cells 
Further confirmation for the differential expression of FFAR1 and FFAR4 in STC-
1 and glial cells was obtained using western blot analysis and specific antibodies to 
FFAR1 and FFAR4. Expression of both FFAR1 (31 kDa) and FFAR4 (42 kDa) was 
detected in homogenates prepared from STC-1 cells (Figure 6).  Similarly expression of 
both FFAR1 (31 kDa) and FFAR4 (42 kDa) was detected in homogenates prepared from 
glial cells (Figure 7). For comparative analysis of FFAR1 and FFAR4 expression in STC-
1 and glial cells, densitometric analysis of FFARs normalized to loading control β-actin 
was performed.  Expression of FFAR4 was 1.62 fold higher compared to FFAR1 in STC-
1 cells.  In contrast, expression of FFAR1 was 2.52 fold higher compared to FFAR4 in 
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glial cells.  The pattern of FFAR1 and FFAR4 protein expression is consistent with the 
pattern of mRNA expression of these receptors in STC-1 and glial cells (Figure 8). 
3.1C. Expression of FFAR1 and FFAR4 in Mouse Intestine 
Immunohistochemical analysis of tissue cryosections obtained from mouse small 
intestine shows the presence of FFAR1 and FFAR4 in specific cells of the mucosal layer 
(Figure 7-11). FFAR1 and FFAR4 positive cells were located in the microvilli and crypts.  
The cells were triangular in appearance and extended from the basal lamina to luminal 
surface, typical of open type of enteroendocrine cells (EECs). Some FFAR1 and FFAR4 
positive cells were located in close proximity to the intestinal epithelium, where enteric 
glial cells are located (Figures 9 and 10). FFAR1 and FFAR4 were also present in the 
core of the villi where subepithelial glial cells themselves are located. The 
immunohistochemistry data confirmed expression of FFAR1 and FFAR4 in native 
enteroendocrine cells and glial cells as well as the enteroendocrine cell line (STC-1) and 
the glial cell line.  
In summary, FFARs are differentially expressed in STC-1 versus glial cells with 
predominant expression of FFAR4 in STC-1 cells and predominant expression of FFAR1 
in glial cells.   Both FFAR1 and FFAR4 are also present in native enteroendocrine and 
glial cells 
 
3.2 Signaling Pathways Coupled to FFAR1 and FFAR4  
 After demonstrating differential expression of FFAR1 and FFAR4 in STC-1 and 
glial cells, further studies were designed to examine the signaling pathways activated by 
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these receptors in both STC-1 and glial cells. Activation of specific G protein(s) and 
signaling pathways downstream of G proteins in response to the endogenous long chain 
fatty acid, linolenic acid (100 µM), was measured.  Since linolenic acid activates both 
FFAR1 and FFAR4 receptors, agonist selective for FFAR1 (GW9508) and FFAR4 
(TUG891), as well as antagonists selective for FFAR1 (GW1100) and FFAR4 (AH7614) 
were used to analyze receptor-selective signaling pathways in both STC-1 and glial cell.  
 
3.2A. Signaling in STC-1 Cells  
(i) Identification of G proteins coupled to FFAR4. Studies in various tissue and 
cell lines suggest that FFAR1 and FFAR4 are coupled to activation of G proteins (Salehi 
et al. 2005 and Hirasawa et al. 2005), but the specific G protein coupled to FFAR4 in 
enteroendocrine cells has not been identified. Membranes isolated from SCT-1 cells were 
incubated with [35S]GTPγS (60 nM) in the presence or absence of linolenic acid (100 µM), 
and FFAR1 or FFAR4 specific inhibitors were added to wells precoated with different Gα 
antibodies. An increase in the binding of [35S] GTPγS complexed to specific Gα antibody 
reflected the activation of the corresponding G protein. Incubation of membrane with 
linolenic acid in the presence of GTPγS caused a significant increase in the binding of 
[35S] GTPγS to Gαq (3967±253 cpm, P< 0.0001, n=6) (Figure 11). There was no increase 
in the binding of [35S]GTPγS to wells coated with antibody to Gαi1-3 complex (Figure 12).  
These results suggest that linolenic acid activates Gq, but not Gi proteins. Linolenic acid-
induced increase in the binding of [35S]GTPγS to Gαq was blocked by a FFAR4 selective 
antagonist (AH7614, 100 µM), but not by a FFAR1 selective antagonist (GW1100, 10 µM)   
These results suggest that,  in STC-1 cells, long chain fatty acid linolenic acid 
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preferentially activates FFAR4 receptors that are coupled to Gq.  The results are 
consistent with the predominant expression of FFAR4 compared to FFAR1 in these cells.  
  (ii) Activation of PI hydrolysis. Previous studies (Kebeda et al. 2012 and Shah 
et al. 2012) in various tissue and cell lines have shown that activation of FFA receptors 
by polyunsaturated fatty acid resulted in stimulation of phosphoinositide (PI)-specific 
phospholipase C (PLC-β) activity, and generation of inositol 1,4,5-trisphosphate (IP3). 
However, to deduce the signaling pathway involved in activation of long chain free fatty 
acid receptors in STC-1 cells, we measured the PLC activity in response to the long chain 
fatty acid natural ligand linolenic acid (100 µM), FFAR4 selective agonist TUG891 (100 
µM), and FFAR4 selective antagonist AH7614 (100 µM). Addition of linolenic acid to STC-
1 cells labeled with [3H]myo-inositol,  caused a significant increase in PI hydrolysis, 
measured as increase in water soluble [3H]inositol (410±40 cpm P<0.001, n=8). Similarly, 
selective agonist for FFAR4 caused an increased in PI hydrolysis (332±81 cpm, n=8). 
(Figure 13)   Linolenic acid-induced increase in PI hydrolysis was significantly blocked by 
the selective FFAR4 antagonist (AH7614, 100 µM) (183±15 cpm, P<0.001, n=8) (Figure 
13). These results suggest that, In STC-1 cells linolenic acid-induced increase in PI 
hydrolysis was mediated via FFAR4.  The results are consistent with activation of Gq by 
linolenic acid via FFAR4 in these cells. 
(iii) Increase in intracellular calcium Activation of PLC-β results in the generation 
of inositol 1,4,5-trisphosphate (IP3) and IP3-dependent Ca2+ release from intracellular 
sarcoplasmic reticulum stores. We next examined the effect of linolenic acid and a 
selective FFAR4 agonist (TUG891) on cytosolic Ca2+ ([Ca2+]i) by calcium imaging using 
Fura-2 AM. An increase in F340/F380 fluorescence intensity ratio reflected an increase 
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in intracellular Ca2+.  Consistent with the activation of PI hydrolysis, addition of linolenic 
acid (100 µM)  or TUG891 to STC-1 cells resulted in a rapid increase in cytosolic Ca2+ , 
n=40 (Figures 14 and 15).  
 
3.2B Signaling in Glial Cells   
(i) Identification of G proteins coupled to FFAR1. Studies in various tissue and 
cells lines suggest that FFAR1 and FFAR4 are coupled to activation of G proteins, but 
the specific G proteins coupled to FFAR1 in enteric glial cells have not been identified. 
Membranes isolated from glial cells were incubated with [35S]GTPγS (60 nM) in the 
presence or absence of linolenic acid, and FFAR1 or FFAR4 specific inhibitors and the 
aliquots were added to wells precoated with different Gα antibodies; an increase in the 
binding of [35S]GTPγS complexes to specific Gα antibody reflected the activation of the 
corresponding G protein. Incubation of membrane with linolenic acid in the presence of 
GTPγS caused a significant increase in the binding of [35S]GTPγS to Gαq (5097 cpm P< 
0.001, n=6). (Figure 16).  There was no increase in the binding of [35S]GTPγS to wells 
coated with antibody to Gαi1-3 complex (Figure 17).  These results suggest that linolenic 
acid activates Gq, but not Gi proteins. Linolenic acid-induced increase in the binding of 
[35S] GTPγS to Gαq was blocked by a FFAR1 selective antagonist (GW1100, 10 µM), but 
not by a FFAR4 selective antagonist (AH7614, 100 µM).   These results suggest that, in 
glial cells, long chain fatty acid linolenic acid preferentially activates FFAR1 receptors that 
are coupled to Gq.  The results are consistent with the predominant expression of FFAR1 
compared to FFAR4 in these cells.  
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 (ii) Activation of PI hydrolysis. To deduce the signaling pathway involved in 
activation of FFAR1 in glial cells, we measured the PLC activity in response to long chain 
fatty acid natural ligand 100 µM linolenic acid, FFAR1 selective agonist GW9508 10 µM, 
and FFAR1 selective antagonist GW1100 10 µM. Addition of linolenic acid to glial cells 
labeled with [3H]myo-inositol, caused a significant increase in PI hydrolysis, measured as 
increase in water soluble [3H]inositol (3191 cpm, P<0.0001, n=8). (Figure 18) Similarly, 
selective agonist for FFAR1 (GW9508, 10 µM) caused an increased in PI hydrolysis (2700 
cpm n=8). Linolenic acid-induced increase in PI hydrolysis was significantly blocked by 
the selective FFAR1 antagonist (GW1100, 10 µM) (1366 cpm, P<0.001, n=8), but not by 
FFAR4 antagonist (AH7614, 100 µM)   (Figure 18). These results suggest that, in glial 
cells, linolenic acid-induced increase in PI hydrolysis was mediated via FFAR1.  The 
results are consistent with activation of Gq by linolenic acid via FFAR1 in these cells.   
Control studies showed that linolenic acid induced increase in PI hydrolysis was blocked 
by the selective PLC inhibitor, U73122 (10 µM) (Figure 19). 
(iii) Increase in intracellular calcium.  Activation of PLC-β results in the 
generation of inositol 1,4,5-trisphosphate (IP3) and IP3-dependent Ca+2 release from 
intracellular sarcoplasmic reticulum stores. We next examined the effect of linolenic acid 
in the presence or absence of FFAR1 antagonist (GW1100, 100 µM) on cytosolic Ca+2 
([Ca+2]i) by calcium imaging using Fura-2 AM. An increase in the fluorescence intensity 
ratio (F340/F380) reflected an increase in intracellular Ca2+. Consistent with the activation 
of PI hydrolysis, addition linolenic acid (50 µM and 100 µM) to glial cells resulted in a rapid 
increase in cytosolic Ca+2 (Figure 20).  The effect of linolenic acid was inhibited in the 
presence GW1100 (Figure 21) suggesting that the effect of linolenic acid was mediated 
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via activation of FFAR1.  In support of this notion, a selective FFAR1 agonist GW9508 
(100 µM) caused an increase in Ca2+ (Figure 22) n=40.  
In summary, both FFAR1 and FFAR4 are coupled to Gαq and stimulation of PLC-
β/IP3/ Ca+2 pathway. In enteroendocrine cells (STC-1) long chain fatty acids preferentially 
activate FFAR4, whereas in glial cells long chain fatty acids preferentially activate FFAR1.  
This is consistent with predominant expression of FFAR4 compared to FFAR1 in STC-1 
cells, and predominant expression of FFAR1 compared to FFAR4 in glial cells.   
 
3.3 Regulation of Brain-derived Neurotrophic Factor (BDNF) Content by Activation 
of Long Chain FFAR in STC-1 and Enteric Glial Cells. 
 There are many hormones, neurotransmitters and neurotrophins that are released 
in response to long chain free fatty acids in gastrointestinal tract. Activation of FFAR1 
induces release of cholecystokinin (Elke Kaemmerer, 2010) and activation of FFAR4 
activation induces release of incretin hormones (Frank Riemann, 2012).  Of the several 
neurotrophins identified, brain-derived neurotrophic factor (BDNF) has been associated 
with regulation of gastrointestinal motility (Grider et al., 2006).  However, the effect of long 
chain free fatty acids on the BDNF content is not known. Several studies have been 
addressed neurotrophins production using different approaches. In our study we used 
mainly two approaches; in the first approach BDNF tagged with green fluorescent protein 
was used to measure BDNF localization and expression in STC-1 and enteric glial cells, 
and in the second approach enzyme-linked immunosorbent assay (ELISA) was used to 
measure BDNF levels in the cell lysates.  
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3.3A. Regulation of BDNF Levels by FFAR4 in STC-1 Cells 
 First we examined the colocalization of BDNF with FFAR4 in cultured STC-1 cells. 
Some, but not all, cells show co-localization of BDNF with FFAR1 (Figure 23). Then, to 
evaluate whether BDNF levels are regulated by activation of FFAR4, STC-1 cells were 
treated for 15 minutes with linolenic acid (100 µM) and number of BDNF immunopositive 
cells were counted.  As shown in Figure 24, treatment of cells with linolenic acid 
significantly increased the number of BDNF positive cell (four folds increase compared to 
control cells) (P<0.0001).   
The immunocytochemistry study results were further confirmed by the 
measurement of BDNF content by ELISA.  Linolenic acid (100 µM) caused a significant 
increase in BDNF (P< 0.01, n=7) (Figure 25). The increase was blocked by selective 
FFAR4 antagonist (AH7614, 100 µM), but not by a selective FFAR1 antagonist (GW1100, 
10 µM), suggesting that, in STC-1 cells, linolenic acid selectively activates FFAR4 to 
increase BDNF levels.  This conclusion was further supported by siRNA approach to 
suppress FFAR4 expression.  As shown in Figure 26, linolenic acid-induced increase in 
BDNF levels was abolished in cells expressing FFAR4 siRNA.  The selective involvement 
of FFAR4 receptors in the regulation of BDNF in STC-1 cells is consistent with the 
predominant expression of FFAR4 in these cells and selective activation of Gq/PLC/Ca2+ 
pathway coupled to FFAR4 by linolenic acid.  
.3.3B. Regulation of BDNF Levels by FFAR1 in Glial Cells 
 First we examined the colocalization of BDNF with FFAR4 in glial cells. Some, but 
not all cells show co-localization of BDNF with FFAR1 (Figure 27). Then, to evaluate 
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whether BDNF levels are regulated by the activation of FFAR1, glial cells were treated 
for 15 minutes with linolenic acid (100 µM) and the number of BDNF immunopositive cells 
were counted.  As shown in Figure 28, treatment of cells with linolenic acid significantly 
increased the number of BDNF positive cell (2.5 fold increase compared to control cells) 
(P<0.0001).   
The immunocytochemistry study results were further confirmed by the 
measurement of BDNF content by ELISA.  Linolenic acid (100 µM) caused a significant 
increase in BDNF (P< 0.01, n=7) (Figure 29).  The increase was blocked by a selective 
FFAR1 antagonist (GW1100, 10 µM), but not by a selective FFAR4 antagonist (AH7614, 
100 µM), suggesting that, in contrast to STC-1 cells, in glial cell linolenic acid selectively 
activates FFAR1 to increase BDNF levels.  This conclusion was further supported by 
siRNA approach to suppress FFAR1 expression.  As shown in Figure 30, linolenic acid-
induced increase in BDNF levels was abolished in cells expressing FFAR1 siRNA.  The 
selective involvement of FFAR1 receptors in the regulation of BDNF in glial cells is 
consistent with the predominant expression of FFAR1 in these cells and selective 
activation of Gq/PLC/Ca2+ pathway coupled to FFAR1 by linolenic acid.  
In summary, in enteroendocrine cells (STC-1), long chain fatty acids increase 
BDNF content via FFAR4, whereas in glial cells they increase BDNF content via FFAR1.  
This is consistent with predominant expression FFAR4 and preferential activation of 
FFAR4 by long chain fatty acids in STC-1 cells and predominant expression of FFAR1 




Figure 1. Cell lines used in this study.  
Photomicrographs of mouse STC-1 cells (enteroendocrine cell line) and rat glial cells 





Figure 2.  Immunohistochemical staining of glial cell markers.    
Enteric glial cells were stained for glial cells markers, glial fibrillary acidic protein (GFAP, 
right panel) and S100 (left panel).  Middle panel: Control staining without primary antibody 















Figure 3. Messenger RNA expression of free fatty acid receptors (FFARs) in STC-1 
cells.  
Total RNA isolated from mouse STC-1 cells was reverse transcribed using 2 µg of total 
RNA using qScript cDNA preparation kit. The cDNA was amplified with specific primers 
for FFAR1, FFAR2, FFAR3, FFAR4, and GPR84 and analyzed on 2% agarose gel 
containing ethidium bromide. The sequence of primers are listed in Table 1. PCR 
products of expected size were obtained with primers for FFAR1 (159 bp), FFAR2 (58bp), 


































Figure 4. Messenger RNA expression of free fatty acid receptors (FFARs) in glial 
cells.  
Total RNA isolated from rat enteric glial cells was reverse transcribed using 2 µg of total 
RNA using qScript cDNA preparation kit. The cDNA was amplified with specific primers 
for FFAR1, FFAR3, FFAR4, and GPR84 and analyzed on 2% agarose gel containing 
ethidium bromide. The sequence of primers are listed in Table 1. PCR products of 
expected size were obtained with primers for FFAR1 (65 bp), FFAR3 (114 bp), GPR84 




MW +RT +RT -RT-RT
Glial cells Rat mucosa
FFAR3
65 bp 114 bp




MW +RT +RT -RT-RT
Glial cells Rat mucosa
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Figure 5. Quantitative PCR (qRT-PCR) of free fatty acid receptors in mouse STC-1 
and rat glial cells.  
Quantitative PCR was conducted in a 20 µl of reaction volume containing Quantitect 
™SYBRgreen PCR Mastermix. Real-time PCR reactions were performed in triplicate. 
Results were expressed as fold change or fold differences in FFARs after normalizing 
with endogenous control, GAPDH or β-actin.  Right panel: Expression in glial cell.  GPR84 
and FFAR4 expression levels with references to FFAR1 after normalizing with 
endogenous control, GAPDH or β-actin. Left panel: Expression in STC-1 cells.  FFAR2, 
FFAR3, FFRA4 and GPR84 expression levels with references to FFAR1.  Expression of 
FFAR1 is higher in enteric glial cells compared to other FFARs whereas expression of 
FFAR4 is higher in STC-1 cells compared to other FFARs. Values represent the means 
±SEM of 4 separate experiments. In glial cells FFAR4 and GPR84 *p<0.05 vs FFAR1 
**p<0.001 vs FFAR1.  
  
 













































Figure 6. Protein expression of free fatty acid receptors (FFARs) in STC-1 cells.   
Cell lysates obtained from cultured mouse STC-1 cells. Equal amounts of total proteins 
were separated with SDS-PAGE and expression of FFAR1 and FFAR4 was analyzed by 
western blot using receptor-specific antibodies. β-actin was used as loading control. 
Protein band of expected size for both FFAR1 (31 kDa) and FFAR4 (42 kDa) was 






















Figure 7. Protein expression of free fatty acid receptors (FFARs) in glial cells.    
Cell lysates obtained from cultured rat glial cells. Equal amounts of total proteins were 
separated with SDS-PAGE and expression of FFAR1 and FFAR4 was analyzed by 
western blot using receptor-specific antibodies. β-actin was used as loading control. 
Protein band of expected size for both FFAR1 (31 kDa) and FFAR4 (42 kDa) was 










 Figure 8. Comparitive quantitative analysis FFAR1 and FFAR4 expression in STC-
1 and glail cells.  
Densitometric analysis of the western blot of FFAR1 and FFRA4 expression Right panel: 
Relative abundance of FFAR4 compared with FFAR1 protein expression in STC-1. Left 
panel: Relative abundance of FFAR1 in glial cells compared with FFAR4 protein 











































Figure 9. Expression of FFAR1 in mouse small intestine by Immunohistochemistry. 
Cryosections of mouse small intestine was stained with FFAR1 antibody and imaged at 
40x magnification.  Some cells contained within submucosal epithelium area where 
enteric glial cells located are also positive for FFAR1.  FFAR1-positive cells are located 







Figure 10. Expression of FFAR4 in mouse small intestine by 
Immunohistochemistry.   
Cryosections of mouse small intestine was stained with FFAR4 antibody and imaged at 
40x magnification. FFAR4-positive cells are located within mucosal of colonic crypt with 
enteroendocrine cell-like morphology.  Some cells contained within submucosal 
epithelium area where enteric glial cells located are also positive for FFAR4.  Arrows 






Figure 11. Activation of Gq protein by linolenic acid via FFAR4 in STC-1 cells. 
Membranes isolated from STC-1 cells were incubated for 30 minutes at 37 C with [35S] 
GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for 
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM).  Aliquots quantity amount of 
protein were added to the wells precoated with the specific antibody to Gαq. The amount 
of radioactivity bound to activate Gαq was measured by liquid scintillation and expressed 
as counts per minutes (cpm).  Linolenic acid (LA) caused a significant increase in the 
binding of [35S] GTPS-Gαq that was blocked by the selective FFAR4, but not FFAR1, 
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Figure 12. Effect of linolenic acid on the activation of Gi protein in STC-1 cells. 
Membranes isolated from STC-1 cells were incubated for 30 minutes at 37 C with [35S] 
GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for 
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM).   Aliquots of equal amounts of 
protein were added to the wells pre-coated with the antibody to Gαi1-3 and incubated for 
two hours. The amount of radioactivity bound to activate Gαi1-3 was measured by liquid 
scintillation and expressed as counts per minute (cpm).  Treatment with LA had no effect 
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Figure 13. Activation of PI hydrolysis by linolenic acid (LA) via FFAR4 in STC-1 
cells.   
Cultured mice STC-1 cells were labeled with myo-[3H] inositol for 24 hours and then 
treated with LA (100 µM), FFAR4 agonist TUG891 (100 µM), or FFAR4 antagonist 
AH7614 (100 µM). PI hydrolysis was measured as increase in water soluble [3H] inositol 
by ion exchange chromatography. Result are expressed as count per minute. Treatment 
of cells with LA caused a significant increase in PI hydrolysis and the increase was 
blocked by the FFAR4 antagonist.  FFAR4 agonist also caused an increase in PI 
hydrolysis. Values are expressed as mean ± SEM of 8 experiments. **P< 0.001; *p<0.01 
































Figure 14. Increase in intracellular calcium by linolenic acid (LA) in STC-1 cells.  
Cultured mouse STC-1 cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in 
in HEPES buffer containing 10% pluronic and DMSO for 3 hours at room temperature. 
Clusters of cells were selected for imaging and visualization. The cells were alternatively 
excited at 340 nm and 380 nm and the increase in cytosolic calcium in response to 
linolenic acid was measured as the increase in the ratio of the fluorescence of fura-2 at 
F340/F380 nm emission at 530 nm. Representative results demonstrated that addition of 










Figure 15. Increase in intracellular calcium by FFAR4 agonist TUG891 in STC-1 
cells.   
Cultured mouse STC-1 cells were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in 
in HEPES buffer containing 10% pluronic and DMSO for 3 hours at room temperature. 
Clusters of cells were selected for imaging and visualization. The cells were alternatively 
excited at 340 nm and 380 nm and the increase in cytosolic calcium in response to FFAR4 
agonist, TUG891 (100 µM) was measured as the increase in the ratio of the fluorescence 
of fura-2 at F340/F380 nm emission at 510 nm. Representative results demonstrated that 

















Figure 16. Activation of Gq protein by linolenic acid via FFAR1 in glial cells. 
Membranes isolated from enteric glial cells were incubated for 30 minutes at 37 C with 
[35S] GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for 
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM).  Aliquots of equal amounts of 
protein were added to the wells pre-coated with the specific antibody to Gαq. The amount 
of radioactivity bound to activated Gαq was measured by liquid scintillation and expressed 
as counts per minute (cpm).  Linolenic acid caused a significant increase in the binding 
of [35S] GTPS-Gαq and the increase in the binding was blocked by the selective FFAR1, 
but not FFAR4, antagonist. Values are expressed as mean ± SEM of 6 experiments. 
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Figure 17. Effect of linolenic acid on the activation of Gi protein in glial cells. 
Membranes isolated from glial cells were incubated for 30 minutes at 37 C with [35S] 
GTPS and 100 µM linolenic acid (LA) in the presence or absence of antagonist for 
FFAR1 (GW1100, 10 µM) or FFAR4 (AH7614, 100 µM).   Aliquots quantity equal amounts 
of protein were added to the wells precoated with the antibody to Gαi1-3 and incubated for 
two hours. The amount of radioactivity bound to activated Gαi1-3 measured by liquid 
scintillation and expressed as counts per minutes (cpm). Treatment with LA had not effect 
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Figure 18. Activation of PI hydrolysis by linolenic acid (LA) via FFAR1 in glial cells.  
Cultured glial cells were labeled with myo-[3H] inositol for 24 hours and then treated with 
LA (100 µM) in the presence or absence of FFAR1 antagonist (GW100, 10 µM) or FFAR4 
antagonist (AH7614, 100µM), or FFAR1 agonist GW9508 (10 µM).   PI hydrolysis was 
measured as increase in water soluble [3H]inositol by ion exchange chromatography. 
Result are expressed as count per minute (cpm). Linolenic acid caused a significant 
increase in PI hydrolysis and the increase was blocked by the FFAR1 antagonist, but not 
FFAR4 antagonist.  FFAR1 agonist also caused an increase in PI hydrolysis. Values are 
expressed as mean ± SEM of 8 experiments. **P< 0.001; *P<0.01 significant increase in 
PI hydrolysis with LA vs basal.  
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Figure 19. Inhibition of linolenic acid-induced PI hydrolysis by non-specifc PLC 
inhibitor U73122 enteric glial cells.  
Cultured glial cells were labeled with myo-[3H] inositol for 24 hours and then treated with 
linolenic acid (LA, 100 µM) in the presence or absence of PLC inhibitor U73122 (10 µM).   
PI hydrolysis was measured as increase in water soluble [3H] inositol by ion exchange 
chromatography. Result are expressed as count per minute. Treatment of cells with LA 
caused a significant increase in PI hydrolysis and the increase was blocked by U73122. 
Values are expressed as mean ± SEM of 8 experiments. **P< 0.001 significant increase 
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Figure 20. Increase in intracellular calcium by linolenic acid (LA) in glial cells.  
Cultured glial cells  were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in in HEPES 
buffer containing 10% pluronic and DMSO for 3 hours at room temperature. Clusters of 
cells were selected for imaging and visualization. The cells were alternatively excited at 
340 nm and 380 nm and the increase in cytosolic calcium in response to linolenic acid 
was measured as the increase in the fluorescence intensity ratio of fura-2 at F340/F380 
nm emission. Representative results demonstrated that addition of LA to glia cells 










Figure 21. Inhibition of linolenic acid-induced Increase in calcium by FFAR1 
antagonist in glial cells.  
 Cultured glial cells  were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in in HEPES 
buffer containing 10% pluronic and DMSO for 3 hours at room temperature. Clusters of 
cells were selected for imaging and visualization. The cells were alternatively excited at 
340 nm and 380 nm and the increase in cytosolic calcium in response to linolenic acid in 
the presence or absence of FFAR1 antagonist GW1100 (10 µM) was measured as the 
increase in the fluorescence intensity ratio F340/F380 nm emission. Representative mean 
results of 40 cells demonstrated that addition of LA to glial cells resulted in a rapid 









































Figure 22. Increase in intracellular calcium by FFAR1 agonist, GW9508 in glial cells.  
Cultured glial cells  were loaded with fluorescent Ca2+ dye fura 2-AM (5 µM) in in HEPES 
buffer containing 10% pluronic and DMSO for 3 hours at room temperature. Clusters of 
cells were selected for imaging and visualization. The cells were alternatively excited at 
340 nm and 380 nm and the increase in cytosolic calcium in response to FFAR1 agonist 
GW9508 (100 µM) acid was measured as the increase in the fluorescence intensity ratio 
at F340/F380 nm emission. Representative mean results of 40 cells demonstrated that 








Figure 23. Colocalization of FFAR4 and BDNF in cultured mouse STC-1 cells. 
Cultured STC-1 cells were stained with primary antibody to BDNF or FFAR4 and 
secondary antibody Flexa 488 (green) for BDNF and Flexa 594 (red) for FFAR4. The cells 
were imaged at x400 magnification. Arrows point to the cells colocalization of BDNF and 







Figure 24. Increase in BDNF positive cells by linolenic acid in STC-1 cells. 
Cultured STC-1 cells were stained with BDNF antibody before and after treatment with 
linolenic acid (100 µM) for 15 min.  The cells were imaged at x400 magnification. Results 
demonstrated an increase in BDNF (green fluorescence) after linolenic acid (LA) 
treatment. Right panel: Quantitative analysis of BDNF positive cells before and after 


























Figure 25. Increase in BDNF content by linolenic acid via FFAR4 in STC-1 cells.    
Cultured STC-1 cells treated with 100 µM linolenic acid (LA) in the presence or absence 
of FFAR4 antagonist (AH7614, 100 µM) or FFAR4 agonist (TUG891, 100 µM) for 15 at 
37°C. The amount of BDNF in the cell lysates was measured by ELISA. Linolenic acid-
induced increase in BDNF content was inhibited by FFAR4-antagonist. Values are 
expressed as mean ± SEM of 3 experiments. *P< 0.05 significant increase of BDNF 

























Figure 26. Increase in BDNF content by linolenic acid via FFAR4 in STC-1 cells.   
Cultured STC-1 cells were transfected with control siRNA for FFAR4 siRNA for 48 h and 
treated with 100 µM linolenic acid (LA) or FFAR4 agonist (TUG891, 100 µM) for 15 at 
37°C. The amount of BDNF in the cell lysates was measured by ELISA. Linolenic acid or 
FFAR4 agonist caused an increase in BDNF content in cells transfected with control 
siRNA but not in cells transfected with FFAR4 siRNA. . Values are expressed as mean ± 
SEM of 3 experiments.  *P< 0.05 significant increase of BDNF versus basal.  #P< 0.05 
significant inhibition of BDNF vs basal.  Inset showing transfection of pSIREN-DNR-




























Figure 27. Colocalization of FFAR1 and BDNF in cultured enteric glial cells.  
Cultured glial cells were stained with primary antibody to BDNF for FFAR1 and secondary 
antibody Flexa 488 (green) for BDNF and Flexa 594 (red) for FFAR1. The cells were 
imaged at x400 magnification. Arrows point to the cells colocalization BDNF and FFAR1. 















Figure 28. Increase in BDNF positive cells by linolenic acid in glial cells. 
Cultured glial cells were stained with BDNF antibody before and after treatment with 
linolenic acid (100 µM) for 15 min.  The cells were imaged at x400 magnification. Results 
demonstrated an increase in BDNF (green fluorescence) after linolenic acid (LA) 
treatment. Right panel: Quantitative analysis of BDNF positive cells before and after 


























Figure 29. Increase in BDNF content by linolenic acid via FFAR1 in glial cells.    
Cultured glial cells treated with 100 µM linolenic acid (LA) in the presence or absence of 
FFAR1 antagonist (GW1100, 10 µM) or FFAR1 agonist (GW9508, 10 µM) for 15 at 37°C. 
The amount of BDNF in the cell lysates was measured by ELISA. Linolenic acid-induced 
increase in BDNF content was inhibited by FFAR1. Values are expressed as mean ± SEM 


























Figure 30. Increase in BDNF content by linolenic acid via FFAR1 in glial cells.   
Cultured glial cells were transfected with control siRNA or FFAR1 siRNA for 48 h and 
treated with 100 µM linolenic acid (LA) for 15 at 37°C. The amount of BDNF in the cell 
lysates was measured by ELISA. Linolenic acid caused an increase in BDNF content in 
cells transfected with control siRNA but not in cells transfected with FFAR1 siRNA. . 
Values are expressed as mean ± SEM of 3 experiments.  *P< 0.05 significant increase of 
BDNF versus basal.  #P< 0.05 significant inhibition of BDNF vs basal.  Inset showing 






























Free fatty acids are essential dietary components that contribute to various cellular 
functions, provide energy to the cell, supply building material for cellular structure 
including membrane and organelles, and regulate cellular metabolism in various 
physiological and pathophysiological conditions. As mentioned in the first chapter, short 
chain fatty acids (SCFAs) are produced during fermentation of resistant starches and 
indigestible fiber by anaerobic gut flora, while long chain fatty acids are generated from 
dietary intake, lipolysis in adipose tissue, and hepatic forms of neutral fats, cholesteryl 
esters and phospholipids.  
A series of experiments demonstrated that individual fatty acids have different 
effects in the nutrient sensing, gastrointestinal motility, hormone/paracrine release and 
function.  For example, administration of the SCFA propionate (C3) caused decreased 
food intake in sheep (Masahito O and Michael A, 2003). Butyrate (C4), at physiological 
concentration of 10 to 30 mM, increased the proximal colon contraction, while acetate 
(C2) and propionate (C3) at the same concentration decreased proximal colon 
contraction, thus decreased the motility (Hurst et al 2014). Long chain fatty acids have 
been reported to play an important role in the regulation of insulin secretion in the 
pancreatic β-cells, in bone inflammation, and omega 3 restrain bone loss (Fabien CJ et 
al. 2013). However, chronic consumption of high fat diet has been attributed to the 
development of several diseases such as Type II Diabetes and obesity. Until the last 
decade, the roles of fatty acids were thought to be mediated exclusively through actions 
on cellular metabolism.  
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 In recent years, characterization and deorphanization of some seven 
transmembrane G-protein coupled receptors (GPCRs) by the identification of FFA ligands 
has provided a new development of the mechanism of action of free fatty acids. They 
serve as not only nutrients and metabolic substrates but also as extracellular signaling 
molecules.  
Upon digestion of food, the gastrointestinal tract represents the first site of 
interaction between ingested nutrients and the host. The dietary fat and fatty acids are 
sensed via binding to specific free fatty acids receptors that are expressed on the surface 
of a variety of epithelial cells in the gut that mediate the release of gut peptides. It has 
been reported that ingested fat induces secretion of gut hormones; CCK from specialized 
enteroendocrine cells, I-cells, glucagon-like peptides and peptide YY from L cells, and 
glucose-dependent insulinotropic peptide from L cells (Liddle RA 1997, Strader AD et al. 
2005 and Sternini C et al. 2008). Cholecystokinin (CCK) the upper small intestinal 
hormone is one of the primary endocrine regulators of small intestinal digestion. It was 
first described as a satiety hormone that plays a role in stimulation of pancreatic secretion, 
inhibition of gastric motility and food intake (Dockray GJ .2003).  
In 2008 Toshiki Tanaka group has been using α-linolenic acid as a long chain free 
fatty acid to examine the role of free fatty acid receptors in secretion of CCK in vitro. They 
have demonstrated that long chain FFAs enhance the CCK secretion in STC-1 cells that 
mainly occurs through FFAR4.  
 Moreover, it has been reported that the secretion of GLP-1 from STC-1 is 
mediated via the activation of FFAR4 (Hirasawa et al. 2005). GLP-1 is a gut hormone is 
released from L cells and has a pivotal role in mediating food stimulated glucose 
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dependent secretion of insulin from pancreatic β cells. Also, GLP-1 has a role in 
stimulating β cells proliferation and differentiation. GLP-1 is considered the most potent 
insulinotropic incretin. Therefore, identification of FFAR4-mediating GLP-1 release 
induced by FFAs is very important in the treatment of diabetes. In addition, a number of 
studies have provided evidence for the importance of FFAR1 and FFAR4 in potentiating 
glucose stimulated insulin secretion via the secretion of GLP-1 and GIP hormones from 
enteroendocrine cells (Itoh et al 2003, Efdalk et al 2008).  
Furthermore, FFAR2 and FFAR3 have been shown to stimulate the release of PYY 
(Kennedy RL et al, 2010). PYY is a neuroendocrine mediator is secreted from 
enteroendocrine cells (L cells) and plays a role in slow gastric emptying and stimulates 
digestion and nutrient absorption in the small intestine.  
Most studies have focused on the role of free fatty acid receptors in energy intake, 
and regulating gastric and intestinal hormone/paracrine release and function. Little is 
known of the presence of free fatty acids receptors in the endocrine cell and enteric glial 
cells in the gut, and their role in regulation of brain derived neurotrophic factor. We 
hypothesize that free fatty acid receptors play a role in the regulation of brain-derived 
neurotrophic factor levels in the enteric glial and endocrine cells. Therefore, we examined 
1) FFAR1, FFAR2, FFAR3, FFAR4 and GPR84 expressions in enteroendocrine cells, 
glial cells and in mouse mucosal cells, 2) the signaling pathway involved in long chain 
free fatty acid receptors FFAR1 and FFAR4 in enteroendocrine cells (STC-1) and enteric 
glial cells, 3) the role of FFAR1 and FFAR4 in the regulation of brain derived neurotrophic 




Expression of FFARs in Enteroendocrine Cell and Enteric Glial Cells  
  In this study, we firstly reported that mRNA levels for FFAR1, FFAR2, FFAR3, 
FFAR4 and GPR84 are expressed differentially in enteroendocrine cell line STC-1 and 
enteric glial cells.  Among several tissues and cell types in different species, various FFA 
receptor gene have been demonstrated. Our data showed an abundant expression of 
FFAR1 mRNA in enteric glial cells with two fold more expression than FFAR4 and GPR84. 
The study from Briscoe et al 2003 and Kotarsky et al 2003 revealed expression of FFAR1 
in the skeletal muscle, liver and heart. TaqMan quantitative PCR showed that FFAR1 
mRNA is predominantly expressed in insulin producing β cells (Itoh et al. 2003). Other 
studies have detected FFAR1 expression in the pancreatic β cell line MIN6, mouse βTC-
3, and rat insulinoma INS-1E cells (Sharipo H et al. 2005). It was also detected in non β-
cells, such as, human breast cancer cell line MCF-7 and enteroendocrine cells 
(Yonezawa T et al. 2004).  
Furthermore, we have demonstrated the expression of FFAR2 mRNA in the 
enteroendocrine cell line STC-1. Other studies also have detected the level of FFAR2 
mRNA in variety of tissues and cell types; such as neutrophils (Brown et al. 2003), skeletal 
muscle and heart (Nilsson et al, 2003), adipose tissue (Hong et al. 2005). FFAR2 has 
also been detected in the breast cancer cell line, MCF-7 (Yonezawa et al. 2006) and in 
rat distal ileum and colon (Karaki et al. 2006).  We also reported the expression of other 
SCFA receptors such as FFAR3 mRNA in the enteroendocrine cells and enteric glial cells. 
Initial studies done on FFAR3 reported highest level of mRNA expression in adipose 
tissue (Brown et al. 2003). The expression was also seen in 3T3-L1 and 3T2-F442A 
adipose cell line (Xiong et al. 2004).  
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Our results and of others have shown FFAR4 mRNA expression was found in 
mouse STC-1 cells. Our studies demonstrated abundant expression of FFAR4 in STC-1 
cells compared with other FFA receptors. This is in contrast to the abundant expression 
of FFAR1 compared to FFAR4 in enteric glial cells (Figure 5). Although the ligand profiles 
were similar for FFAR1 and FFAR4, both receptors were activated by long chain fatty 
acids, however, the amino acid homology between both receptors was only 10% (Hara T 
et al. 2009). Consistent with our data, FFAR4 was found to be expressed in the mouse 
intestinal tract with abundant expression in the murine enteroendocrine STC-1 cells 
(Hirasawa et al. 2005, Gotoh C et al. 2007, and Miyauchi et al. 2009).  
Furthermore, in our studies the medium chain free fatty acid receptor, GPR84 
mRNA was expressed in both enteroendocrine cells and enteric glial cells. Other studies 
have shown the expression of GPR84 in various tissues such as heart, lung, liver, and 
leucocytes. In particular, inflammatory cells, granulocytes, T and B cells also express 
GPR84 (Yousefi B et al. 2001; Venkataraman and Kuo 2005).  
Consistent with differential expression of mRNA levels of FFAR1 and FFAR4 in 
our STC-1 and glial cells, results from protein expression showed the same distribution 
and differential expression. FFAR1 protein level was higher in enteric glial cells while 
FFAR4 protein level was more in STC-1 cells (Figure 8). Taken together, our expression 
results suggest that there is a different role and mechanism of each FFA receptors in 
different cells. Thus, we examined the signal transduction of long chain FFAR1 in enteric 




Signaling Mechanisms Downstream of FFAR1 and FFAR4 
This is the first study to demonstrate the effects of long chain fatty acids (linolenic 
acid) on enteric glial cells. Our studies demonstrate that FFAR1 are coupled to pertussis 
toxin (PTx)-insensitive Gq protein (Figure 16). FFAR1 activation caused an increase in 
PLC-β activity (PI hydrolysis) in enteric glial cells (Figure 18). Moreover, calcium release 
in response to linolenic acid and FFAR1 agonist was decreased with administration of 
FFAR1 antagonist (Figure 20-22). Several studies on the mechanism of activation FFAR1 
via long chain fatty acid have been reported that FFAR1 is coupled to the G protein 
subunit Gαq, and leads to release of intracellular calcium (Fuijwara et al. 2005; Mancini 
AD and Poitout V 2013). Our studies provided a more detailed analysis of the signaling 
pathways and demonstrated for the first time that long chain fatty acids initiate signaling 
pathway via FFAR1 in enteric glial cells.   
On the other hand, our studies demonstrate that activation of FFAR4 in 
enteroendocrine cells via long chain fatty acid linolenic acid leads to activation of the 
Gq/PLC-β/Ca2+ pathway. These conclusion were reached through several lines of 
evidence: (1) Abundance expression of FFAR4 in STC-1 cells (Figure 5 and 8), (2) 
selective activation of Gq and stimulation of PI hydrolysis (Figure 13). (3) Calcium release 
in response to linolenic acid and FFAR4 agonist (Figure 14 and 15). These data are 
consistent with previous studies that showed FFAR4 expression in HEK293 cells is 
coupled to Gq and promotes elevation of intracellular calcium. It is noteworthy, that in the 
preset study, we used linolenic acid, a natural agonist of long chain FFA receptors that 
can activate both FFAR1 and FFAR4.  
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Taken together, our studies imply that both FFAR1 and FFAR4 are coupled to Gαq 
that stimulates of PLC-β/IP3/ Ca+2 pathway. In enteroendocrine cells (STC-1) long chain 
fatty acids preferentially activates FFAR4, whereas in glial cells long chain fatty acids 
preferentially activates FFAR1.  This is consistent with the predominant expression of 
FFAR4 compared to FFAR1 in STC-1 cells, and predominant expression of FFAR1 
relative to FFAR4 in glial cells. 
 
Regulation of Brain-derived Neurotrophic Factor (BDNF) Content by FFAR1 and 
FFAR4 in STC-1 and Enteric Glial Cells  
The discovery of FFAR1 and FFAR4 in the epithelial layer of the gastrointestinal 
tract has expanded the field of intraluminal nutrient sensing. Upon ingestion of food, 
chemosensory cells scattered throughout the gastrointestinal tract make direct contact 
with the gut lumen and their activation triggers the release of gastrointestinal regulatory 
peptides, neurotransmitters and neurotrophins. One of those is brain derived neurotrophic 
factor (BDNF).  
As outlined in the introduction, BDNF is a neurotrophin present in the intestine 
where it participates in the survival and growth of enteric neurons, and stimulation of 
intestinal peristaltic reflexes and propulsion (Alqudah M et al. 2015).  The physiological 
role of BDNF in the peristaltic reflex has been examined in genetically modified mouse. 
Mouse deficient in BDNF (BDNF+/-) which have reduced peristalsis, release of 5-HT and 
slower velocity of propulsion of fecal pellets compared with wild type BDNF+/+ mice (Goggi 
J et al. 2002 and Grider et al. 2006). Furthermore, BDNF release in the gut has been 
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demonstrated from mucosal enteroendocrine cells and from intrinsic primary afferent 
neurons innervating the mucosa of rat and mouse colon in response to mucosal 
mechanical stimulation (Grider et al. 2006). Within this context, the role of BDNF is to 
augment release of 5-HT and CGRP, thereby augmenting peristaltic reflex leading to 
enhanced propulsive motility (Grider et al. 2006).  
 Beside the motility effect of BDNF, the localization of BDNF in enteric neurons 
suggests that BDNF may acts as neurotransmitter or neuromodulator in the gut, similar 
to the notion of BDNF in the central nervous system. BDNF could be secreted from enteric 
neurons and can activate the release of CGRP in an autocrine manner, or it could be 
secreted from mucosal cells and act in a paracrine manner.  Three different groups have 
identified BDNF in the glial cells and in endothelial cells (Lucini C et al, 2002, and 
Lommatzch M et al, 1999).   
In the present study, we have demonstrated the colocalization of BDNF with the 
FFAR4 in the STC-1 cells (Figure 23) and colocalization of BDNF with the FFAR1 in the 
glial cells (Figure 27).  
It is not known whether BDNF content level is regulated by the long chain free fatty 
acids via FFAR1 and FFAR4.  The present study has demonstrated the functional role of 
activated FFAR1 and FFAR4 in BDNF regulation in both STC-1 and glial cells. The series 
of experiments demonstrated that the natural agonist, long chain fatty acid, linolenic acid, 
administration caused an increase in BDNF content level in STC-1 via FFAR4. The 
increase in BDNF in response to linolenic acid was demonstrated by both 
immunocytochemistry and measurements of BDNF by ELISA.  The specific role of FFAR4 
in the regulation of BDNF levels in STC-1 cells was demonstrated using both 
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pharmacological and molecular approaches.  A selective FFAR4 antagonist, but not the 
FFAR1 antagonist, and silencing FFAR4 expression blocked the effect of LA on BDNF 
(Figures 25 and 26).  Linolenic acid also caused an increase in BDNF content in glial 
cells.  Increase in BDNF in response to linolenic acid was demonstrated by both 
immunocytochemistry and measurements of BDNF by ELISA. The specific role of FFAR1 
in the regulation of BDNF levels in glial cells was demonstrated using both 
pharmacological and molecular approaches.  A selective FFAR1 antagonist, but not the 
FFAR4 antagonist, and silencing FFAR1 expression blocked the effect of LA on BDNF 
(Figures 29 and 30).  These results are consistent with the predominant expression of 
FFAR4 and selective activation of FFAR4 by linolenic acid in STC-1 cells, and with the 
predominant expression of FFAR1 and selective activation of FFAR1 by linolenic acid in 
glial cells. 
In conclusion, the presented findings indicate the cell-specific expression of FFARs 
in STC-1 cells and glial cells, and their colocalization with BDNF, and the role of FFARS 
in the regulation of BDNF levels.  Given the importance of enteroendocrine cells and glial 
cells as well as BDNF in the regulation of motility, secretion and energy metabolism, our 
studies underscore the physiological importance of free fatty acids and their receptors 
regulation of  gastrointestinal functions. Our results potential suggest new therapeutics 
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